A runtime alterable epidemic model with genetic drift, waning immunity, and vaccinations

Wayne M. Getz^{1,2,3}, Richard Salter^{3,4}, Ludovica Luisa Vissat¹, James S. Koopman^{5,6}, Carl P. Simon^{6,7,8}

¹Dept. ESPM, UC Berkeley, CA 94720-3114, USA

²School of Mathematical Sciences, University of KwaZulu-Natal, South Africa

³Numerus, 850 Iron Point Rd., Folsom, CA 95630, USA

⁴Computer Science Dept., Oberlin College, Oberlin, Ohio, OH 44074, USA

⁵School of Public Health, University of Michigan, Ann Arbor, MI 48109, USA

 $^6\mathrm{Center}$ for the Study of Complex Systems, University of Michigan, Ann Arbor, MI 48109, USA

⁷Gerald R. Ford School of Public Policy, University of Michigan, Ann Arbor, MI 48109, USA

 $^{8}\mathrm{Department}$ of Mathematics, University of Michigan, Ann Arbor, MI 48109, USA

Corresponding Author: Wayne M. Getz, wgetz@berkeley.edu

Author Contributions: JSK and CPS initiated the project, provided feedback on early drafts and participated in discussions. WMG designed and formulated the M-SEIR IBM model, drafted the manuscript, ran simulations, and produced the figures. RS designed and built the RAMP platform and wrote the code and informational text. LLV checked all the mathematical equations and code. Both RS and LLV contributed to the structure of the manuscript. All authors contributed to editing and adding text as needed.

Competing Interest Statements: none

Keywords: SEIR models, Individual-based models, escape mutations, RAMPs, SARS-CoV-2, variant dynamics

Submitted on August 12, 2021

Getz et al.

¹ Abstract

In this paper, we present methods for building a Java Runtime-Alterable-Model 2 Platform (RAMP) of complex dynamical systems. We illustrate our methods by building a multivariant SEIR (epidemic) RAMP. Underlying our RAMP is an individual-based model that includes adaptive contact rates, pathogen genetic drift, waning and cross immunity. Besides allowing parameter values, process descriptions, and scriptable runtime drivers to be easily modified during simulations, our RAMP is easily integrated into other computational platforms, such 8 as our illustrated example with R-Studio. Processes descriptions that can be runtime altered within our SEIR RAMP include pathogen variant-dependent 10 host shedding, environmental persistence, host transmission, and within-host 11 pathogen mutation and replication. They also include adaptive social distanc-12 ing and adaptive application of vaccination rates and variant-valency of vaccines. 13 We present simulation results using parameter values and process descriptions 14 relevant to the current COVID-19 pandemic. Our results suggest that if wan-15 ing immunity outpaces vaccination rates, then vaccination rollouts may fail 16 to contain the most transmissible variants, particularly if vaccine valencies do 17 not adapt to escape mutations. Our SEIR RAMP is designed for easy-use by 18 individuals and groups involved in formulating social-distancing and adaptive 19 vaccination rollout policies. More generally, our RAMP concept facilitates con-20 struction of highly flexible complex systems models of all types, which can then 21 be easily shared among researchers and policymakers as stand alone applications 22 programs. 23

²⁴ 1 Introduction

Kermack and McKendrick pioneered the application of differential equations 25 to modeling the dynamics of disease systems that included susceptible (S), in-26 fected/infectious (E/I) and recovered (R. we use V to include vaccinated) classes 27 of individuals [1]. Subsequent extensions of their formulation include, inter alia, 28 additional disease and demographic classes [2], multihost and pathogen strain 29 considerations [3,4], spatial heterogeneity [5,6], network [7] and individual-based 30 formulations [8,9]. Along with these extensions has come the challenge of "not 31 being able to see the forest for the trees" when questions beyond those pertain-32 ing to the profiles of epidemics on homogeneous, well-mixed, large populations 33 arise. As with the current COVID-19 pandemic, these questions may relate to 34 the emergence of new pathogen variants [10], the effects of waning and cross-35 immunity in hosts with different exposure histories to these variants [11], differ-36 ential transmission and virulence of these variants, issues of spatial heterogeneity 37 and host heterogeneity related to age, gender, and health status factors [12]. 38

We only have the capacity from both technology and human comprehension points of view to understand at any one time how a limited number of factors may explain or affect epidemiological outcomes when measures are applied to mitigate the severity of disease outbreaks. Thus, we are brought to consider the issue of how to craft a model so that it has the "appropriate level of complexity" to address the questions at hand [13,14]. We otherwise follow Einstein's dictum that "models should be as simple as possible, but no simpler."

To facilitate the processes of both "incorporating complexity into" and "strip-46 ping complexity out of" models, we have developed the concept of a Runtime 47 Alterable Model Platform (RAMP). This allow us to focus on outcomes rather 48 than on the logistics of modifying and coding models and carrying out compara-49 tive analyses. Our RAMP includes panels, windows and sliders that allow users 50 51 to specify and manipulate model parameter values, modify process function descriptions, and scripting drivers for implementing sets of simulations. Further, 52 modifications can be made both at the start of and during the course of a sim-53 ulation, while protecting the integrity of the underlying code. In addition, our 54 RAMP automates documentation of all parameter values, process descriptions, 55 changes and actions (modifications and substitutions during simulation) in a 56 file that is then saved at the end of each simulation. This file is then ready for 57 later comparative analyses across sets of simulations, or within data process-58 ing environment that incorporate our RAMP as a component package, such as 59 R-Studio. 60

RAMPs can be developed for models that address classes of problems, formu-61 lated using a Goldilocks principle. Thus, these classes should not be too general 62 so that comparisons within each class require extensive alterations to models 63 (members of the class should share significant structural properties with regard 64 to process dynamics), but also not too specialized so that comparisons across 65 members of the class are too limited to provide answers to question of inter-66 est. Thus we might develop different RAMPs to study genetic, morphogentics, 67 epidemiological, evolutionary, geological, and environmental processes. 68

⁶⁹ Here we provide an example of a RAMP that has sufficient breadth to inves-⁷⁰ tigate an array of questions pertaining to multivariant epidemiological dynam-

Submitted on August 12, 2021

Getz et al.

ics for directly transmissible diseases, such as the current SARS-CoV-2 pan-71 demic [15, 16], influenza [17], or Ebola [13, 18]. For simplicity, we refer to this as 72 our M-SEIR (multivariant susceptible-exposed-infected-recovered) RAMP. For 73 the study of water-borne or vector-borne diseases, similar but somewhat more 74 complicated RAMPs will need to be developed. Our M-SEIR RAMP is designed 75 to be used by individuals either with no coding skills, or with minimal coding 76 skills if they desire to modify some of the process descriptions incorporated into 77 the supplied platform. It is sufficiently detailed, however, to allow the user to 78 incorporate either supplied or user-altered versions of the following processes: i) 79 80 pathogen variant-specific shedding [19], environmental persistence [20], withinhost replication [21] and mortality rates [22]; ii) immunological waning with 81 variant cross immunity [23,24]; iii) pathogen variant drift during transmission 82 and within-host replication [25]; iv) an adaptive contact rate [26]; v.) a time-83 dependent, uni- or multivalent vaccine rollout [27,28] (Fig. 1; for mathematical 84 details see Materials and Methods, as well as our Supplementary Online File-85 here forth referred to as SOF—Appendix A). 86




Figure 1: An overview of the processes included in our M-SEIR model (see Table 1 for equation references.) The probability $\pi_{ih,jl}^{\inf}$ of A_h being infected primarily with pathogen ℓ in terms of receiving an effective dose from agent A_i is computed in terms of a concatenation of shedding rates $(\zeta_{i\ell})$, environmental persistence rates (η_{ℓ}) , and host transmission $(\beta_{h\ell})$ processes (SOF Eq. A.12) and includes both waning and cross immunity factors. The probability $\pi_{h\ell\ell'}^{inv}$ that the dominant variant emerging in host A_h is variant ℓ' given initial infection with variant ℓ is computed in terms of withinhost mutation and within-host replication process (SOF Eq. A.13) and also includes both waning and cross immunity factors. These two probabilities are then used to compute the overall probability $\pi_{ih,j\ell'}$ (SOF Eq. A.14) that infector *i*, infected with major variant *j*, infects infectee *h* with major variant ℓ' . The quantity $R_{\text{eff}}(t')$ is the expected number of individuals each infectious agent is expected to infect around time $t' \in [t + \sigma_{\text{E}}, t + \sigma_{\text{E}} + \sigma_{\text{I}}]$, where $R_0 = R_{\text{eff}}(0)$ is estimated for our model using SOF Eq. A.26.

87

The reason for our inclusion of an adaptive contact rate process is that

Submitted on August 12, 2021

the local nature of contact rate patterns is well established as an important 88 driver of outbreak dynamics [15]. If contact rates remain unchanged during 89 the course of an epidemic, then a classic incidence curve (as in Fig. 2) will 90 be the result. However, repeated peaks associated with consecutive outbreak 91 waves arise as a results of implementing and then relaxing social distancing 92 measures [15]. In the absence of social distancing drivers, which vary greatly 93 from one location/region/country to another, an automated way to evaluate the 94 effects of social distancing measures is through an adaptive contact process of 95 the type that we include in our M-SEIR RAMP. 96

To illustrate the application of our M-SEIR RAMP, we used it to explore 97 aspects of disease incidence and prevalence profiles using parameters that are ap-98 plicable to the SARS-CoV-2 pathogen at the start of the COVID-19 pandemic. 99 For example, we compare constant and adaptive (viz., prevalence dependent) 100 contact rate processes under different waning immunity scenarios. We also ex-101 plore the emergence of variants for different mutation and variant transmission 102 rates. Additionally, we show how our M-SEIR RAMP can be used to evaluate 103 the efficacy of uni- and multivalent vaccines applied at various time-dependent 104 rates, where choice of valency may switch in response to realtime monitoring 105 and surveillance data. Such adaptive vaccination programs may be required 106 to combat the evolutionary arms race between vaccine efficacy and the evolu-107 tion of new pathogen variants [25, 28, 29]. We hope, however, that our results 108 and subsequent investigations using our M-SEIR RAMP provide the kinds of 109 quantitative analyses that can help formulate highly effective local or country 110 level vaccination programs that avoid some of the vaccination rollout pitfalls 111 revealed by our analysis, as well as encourage the adoption of effective adaptive 112 vaccination programs. 113

¹¹⁴ 2 Materials and Methods

¹¹⁵ 2.1 Our M-SEIR in a nutshell

We constructed an individual-based model (IBM) of a susceptible-exposed-116 infectious-recovered (i.e., an SEIVD model, where removed R are split into 117 V=immune/vaccinated, and D=dead) epidemiological process [30, 31] in a ho-118 mogeneous population with a random encounter contact rate parameter $\kappa_0 > 0$. 119 Our formulation allows for the emergence of multiple variants of the pathogen 120 during a concatenation of process depicted in Figure 1 and listed in Table 121 1. Specifically, our formulation includes a host immunological waning pro-122 cess [23,32] and a mutational process that impacts both transmission of mutant 123 variants from the infectee and genetic drift [11, 24, 33] of variants within the 124 infector, with rates impacted by cross immunity effects. We also allowed for 125 variation in pathogen variant transmissibility (i.e., in the $\beta > 0$ parameter of 126 the frequency dependent transmission function $\beta SI/N$ [34, 35]) and pathogen 127 virulence as represented by the disease-induced host mortality rate in the sense 128 of Anderson and May [36] (and often represented by a parameter $\alpha \geq 0$ [34]). 129

The detailed formulation of our model and its algorithmic implementation is provided in Appendix A (SOF), with references to relevant equations in this provided in Table 1. In a nutshell we:

	1	
133	1.	defined a set of 2^J pathogen variants (user selected value for variant en-
134		tropy J ranging from 0 to 7; pathogen index $j = 0,, 2^J - 1$) with
135		a genetic-relatedness topology of a <i>J</i> -dimensional unit cube—i.e., each
136		pathogen has J-loci that can take on one of two allelic values at each
137		locus with immediate neighboring variants differing from each other by
138	~	exactly one allelic value $(0 \text{ or } 1)$ at only one of the J loci
139	2.	defined a population of N_0 hosts as belonging at time t to either an epi-
140		demiologically naïve set of susceptible individuals S of size $N_{\rm S}(t)$, a set
141		A of $N_{\rm A}(t)$ identified agents A_i $(i = 1,, N_{\rm A}(t))$ whose epidemiological
142		histories are known, or a set D of $N_{\rm D}(t)$ individuals that have died from
143		the disease
144	3.	allowed pathogen variant-specific transmission "force" ($\beta_j > 0$) and viru-
145		lence $(\alpha_j \ge 0)$ parameters to vary in value among one another within a
146		defined range $\beta_j \in [\beta_{\min}, \beta_{\max}]$ and $\alpha_j \in [\alpha_{\min}, \alpha_{\max}]$
147	4.	kept track of the total prevalence $N_{\rm I}$ as the sum of the prevalences of the
148		individual variants N_{I_j} , $j = 0,, 2^J - 1$ —i.e. $N_{I} = \sum_{j=0}^{2^J - 1} N_{I_j}$
149	5.	introduced a random contact rate function $\kappa(t)$ with a constant param-
150		eter κ_0 that is Poisson distributed on $[t, t+1), t = 0, 1, \cdots$, multiplied
151		by an adaptive response function that reduces the contact rate with in-
152		creasing disease prevalence, such that the $\kappa(t)$ is reduced to $\kappa_0/2$ when
153		the $N_{\rm I}(t)/(N_0 - N_{\rm D}) = p_{\rm I}^{\rm half}$ —see SOF Eq. A.7
154	6.	updated the epidemiological state of the agents A_i with respect to each of
155		the variants $j = 0,, 2^{J} - 1$, where the state with respect to particular
156		variant j at time t is represented by a list that includes the following J
157		entries pertain to the state of A_i with respect to pathogen variant $j =$
158		$0, \dots, 2^J - 1$. If the j^{th} entry is:
159		(a) 0, then agent A_i has never been infected with this variant
160		(b) $E_j(t, \tau_{ij})$, was infected at time $\tau_{ij} \leq t$ with this variant, but is not
161		yet infectious for an expected period of $\sigma_{\rm E}$ units of time
162		(c) $I_j(t, \tau_{ij})$, then agent A_i was infectious at time t with this variant, for
163		an expected period of $\sigma_{\rm I}$ units of time, having been most recently
164		infected (reinfections with the same variant may occur) with this
165		variant at time $\tau_{ij} < t$
166		(d) $V_j(t, \tau_{ij})$, then agent A_i has now recovered from its most recent in-
167		fection at time τ_{ij} with this variant and has some level of waning
168		immunity to it
169	7.	assumed that agent A_i can be infectious at time t with at most one dom-
170		inant variant (denoted by the index j), although due to mutational pro-
171		cesses this agent may infect other agents with variants related to this dom-
172		inant variant at much lower rates (i.e., through application of a mutation
173		factor $\mu \ll 1$, applied in our basic model through Eq. A.13)
174	8.	assumed that agent \mathbf{A}_i will have different levels of waning immunity to all
175		of the variants to which it has been infected in the past
176	9.	included waning immunity functions $\omega_{ij}(t)$ (symbol is omega: SOF Eq. A.6)
177		used to compute the level of immunity that agent A_i has to its most recent
178		infection by variant j
179	10.	included cross immunity effects (a J^2 -matrix C) that apply both to the
180		<i>infector</i> transmitting the pathogen and the <i>infectee</i> being invaded (inv; its

Submitted on August 12, 2021

181 182 183 184 185 186 187 188 189	11.	"airport code" as described in SOF Fig. B.3) by the pathogen of interest, both of which reduce the likelihood of infection and variant drift by variant <i>j</i> compared with closely related variants ℓ (for a simple example of the matrix <i>C</i> , see Eq. 1 in Section 3 below) computed an <i>infection probability</i> $\pi_{ih,j\ell}^{inf}$ that agent A _i infected with variant <i>j</i> infects agent A _h with variant ℓ in terms of a concatenation of infector viral shedding ($\zeta_{i\ell}$; for a simple example see Eq. 6 in Section 3 below), viral persistence in the environment (η_{ℓ}), and viral transmission ($\beta_{h\ell}$) processes (Fig. 1)
190 191 192 193 194 195 196 197		computed an <i>invasion probability</i> $\pi_{h\ell\ell'}^{\text{inv}}$ that an agent A_h infected with variant ℓ becomes infectious with variant ℓ' as its major variant, in terms of the multiplicative effects of viral mutation (μ) and replication (λ_{ℓ}) pro- cesses ongoing within an infectee A_h during this infectees exposed ($E_{\ell'\tau_{h\ell'}}$) and infectious ($I_{\ell'\tau_{h\ell'}}$) periods (Fig. 1) computed the overall probability $\pi_{ih,j\ell'}$ that an infector A_i infected with major variant j results in an infectee A_h expressing ℓ' as its major variant
198 199 200 201 202 203 204 205 206 207 208		assumed that waning and cross immunity to a particular variant is the same for both natural infections and vaccinations that use the antigen associated with that variant (of course we can easily extend our model to remove this assumption once data become available to support different waning and cross immunity rates for natural infections and particular vaccines) implemented a discrete time individual-based stochastic SEIVD (here V represents individuals that have either recovered from infection or have been vaccinated, D represents cumulative dead; also see [37]) multivariant model that includes specifiable time-dependent univalent and multivalent vaccination implementations

209 2.2 Our RAMP implementation

226

Models of systems process can be coded as singular implementations model for-210 mulations using: i) highly efficiently compilable computer languages (e.g., C++, 211 FORTRAN, Java); or ii) less efficiently, but more easily coded, scriptable (e.g., 212 JavaScript, Python, Perl) computer languages. More conveniently and expedi-213 tiously, they can be coded up, as discussed in [38], using a systems modeling 214 platform, such as Matlab's SIMULINK, Mathematica, Stella, AnyLogic, Nu-215 merus, or Berkelev Madonna. Advantages of the latter include more rapid and 216 accurate model development, though simulations may be slowed down by plat-217 form overhead. Between these extremes, we propose a more general approach 218 to specific classes of systems' models, where the basic system structure is fixed, 219 but implementation of some elements can be easily and safely altered so that 220 optional implementations are presented at runtime. We call such a design run-221 time alterable-model platforms. (RAMPs); and here we present a Java RAMP 222 implementation of the M-SEIR described in the previous subsection. 223

The characteristics we envision for a model platform to be a RAMP are:

- 1. RAMPs include a set of model parameters (constants) whose values can
 - be selected or specified (sometimes within a predefined range of values)

Submitted on August 12, 2021

227

228

229

230

231

232

233

234

235

236

237

238

239

240

242

243

244

245

246

Getz et al.

Symbols	Variables and indices	Equation
		(See SOF)
Variables		
t	time (variable and function values depend on time	/
$N_{\rm S}, N_{\rm A}, N_{\rm D}$	size of sets \mathbf{S} , \mathbf{A} and \mathbf{D}	Eq. A.1
J,j,m,ℓ and ℓ'	variant entropy and indices $(0,, 2^J - 1)$	Eq. A.2
$N_{\mathrm{I}}, N_{\mathrm{I}_{j}}$	total and variant j infectious class size	
A_i, A_h	specific agents $i, h = 1,, N_A(t)$ in set A	Eq. A.4
Functions (if a p	arameter now it may be elaborated later as a fun	ction)
κ	adaptive contact rate	Eq. A.7
ω_{ij}	waning immunity of A_i w.r.t. variant j	Eq. A.6
c_{mj}	cross immunity encountered by variant j when agent previously infected with variant m	Eq. A.8
ϕ_{ij}	immunity modifier	Eq. A.8
ζ_{ij}	shedding rate of variant j by infector A_i	Eq. A.9
η_ℓ	environmental persistence	Eq. A.10
$\beta_{h\ell}$	variant transmission to infectee A_h	Eq. A.11
$\pi^{\inf}_{ih,j\ell}$	probability A_i infects A_h	Eq. A.12
μ	mutation process factor	Eq. A.13
$\lambda_{\ell'}$	within-host replication rate	Eq. A.13
$\pi^{ ext{inv}}_{h\ell\ell'}$	probability ℓ' is major variant when ℓ invades	Eq. A.13
$\pi_{ih,j\ell'}$	probability ℓ' is major variant in A_h when j is major variant in A_i	Eq. A.14

Table 1: Variables, indices and functions in our M-SEIR RAMP

at simulation runtime using a switch, nob, slider, or text-entry window accessed via a platform graphical interface or dashboard (e.g., see Fig. 2 and Table 1 which apply to our M-SEIR RAMP).

2. RAMPs include a specific set of *runtime alternative modules*, (RAMs), where the original can be redefined in a graphical interface window, and the unaltered original and the alternative routines are stored as a (preferably open-ended) numbered set. The original or any one of the alternatives can be selected for use at runtime (for a list of functions in our RAMP see Table 2).

3. RAMP implementations also provide an API for both remote and onboard scripting. This API enables control of all user aspects of the simulation, including the parameter set, run management, RAM options, and data retrieval. Script logic can alter parameter settings and RAM options as the simulation progresses. A Nashorn-based Javascript interpreter enhanced with API methods is provided.

4. The API can be accessed remotely using operating system facilities by external applications running concurrently with the simulator. Of particular interest is the ability to control the simulation from the R statistical platform. An R routine can be formulated to both manage the simulation run and to retrieve and process the resulting data. The RAMP simulation

Submitted on August 12, 2021

Getz et al.

becomes a "virtual package" to the controlling R logic. See SOF Appendix
B.

We implemented our RAMP using Java and made ample use of all of the 249 features described above. Use of the RAM facility permitted experimentation 250 with the several versions of cross immunity (e.g., Eqs.1 and 2). A Javascript 251 program was used to control an adaptive vaccination strategy. A small R pack-252 age serving as a driver was used in an R program that ran the simulations 253 multiple times, extracted results into R data structures, and produced graphs 254 showing statistical mean and standard deviation. More details on the graphical 255 structure and implementation of our M-SEIR are provided in the presentation 256 of both the results below and information in SOF Appendix B. 257

258 2.3 Simplifications and Running the model

In the examples presented in the next section, we have not taken advantage 259 of the full complexity of the model. Thus, for example, in our multivariant 260 simulations we have assumed that all variants are shed at the same relative 261 rate (i.e., $\zeta_{ij} = 1$ for relevant i and $j = 0, ..., 2^J - 1$), have the same environmental persistence properties (i.e., $\eta_{\ell} = 1$ for all $\ell = 0, ..., 2^J - 1$), the same 262 263 within host replication rates (i.e., $\lambda_{\ell'} = 1$ for all $\ell' = 0, ..., 2^J - 1$), and are all 264 equally virulent (i.e., $\alpha_i = \alpha$ for all $j = 0, ..., 2^J - 1$). Obviously, these assump-265 tions can be relaxed once suitable data are available for a particular pathogen 266 to support variant specific shedding, persistence, within-host replication, and 267 virulence values. 268

Further, in the absence of the kind of cross-immunity data obtained from cross-neutralization studies to be able to fit values to the cross-immunity parameters c_{mj} in the cross-immunity matrix **C** we contrast the following two crossimmunity scenarios with respect to a global cross-immunity constant $c \in (0, 1)$. The first we call *cascading* cross-immunity since the level of cross-immunity diminishes multiplicatively with genetic distance of the two strains: viz.

Cascading **C**:
$$c_{mj} = \begin{cases} 1 & \text{if } j = m \\ c^k & \text{if } j \text{ differs from } m \text{ by } k \text{ alleles} \end{cases}$$
 (1)

The second we call *escaping* cross-immunity since when the final allele in the array of J loci mutates from 0 to 1, it escapes completely from cross neutralization effects with all strains that have the original allele at the J^{th} locus: viz.

Escaping C:
$$c_{mj} = \begin{cases} 1 & \text{if } j = m \\ 0 & \text{if } j \ge 2^{J-1} \text{ and } \ell < 2^J \text{ provided } J > 2 \\ c^k & \text{otherwise, where } j \text{ differs from } m \text{ by } k \text{ alleles} \end{cases}$$
(2)

Obviously, this is an idealization of the *escape mutation* phenomenon, which we set up here to enable us to evaluate behavior of such mutations. For the purposes of this paper, idealized escape mutations are defined as those whose level of cross-immunity with the variants from which they arise is 0 (in reality some small level of cross immunity may remain).

Also, in the absence of comprehensive data that allows us to use realistic estimates for the relative transmissibility β_j and virulence α_j of various variants

Submitted on August 12, 2021	Getz et al.
------------------------------	-------------

j = 0, ..., J, we employ the following scenario facilitating formulations. These permit us to investigate the potential impacts of increased transmission and virulence with the emergence of new strains based on the number of mutations d_i needed to get from variant 0 to variant j. Specifically, for

$$d_j =$$
 Hamming distance between variants 0 and j (3)

and for transmissibility and virulence perturbation parameters δ_{β} and δ_{α} respectively, we define

Transmissibility:
$$\bar{\beta}_i = \beta (1 + \delta_\beta)^{d_j}$$
 (4)

(the bar notation here reminds us that this value is used in the computation of β_{ij} according to equation Eq. A.8) and

Virulence:
$$p_{\alpha_j} = p_{\alpha_j} (1 + \delta_\alpha)^{d_j}$$
 (5)

(this is a probability rather than a rate and we have to ensure δ_{α} is selected such that $p_{\alpha_i}(1+\delta_{\alpha})^J \leq 1$).

Also for simplicity's sake we assumed that infectee with major variant j will shed minor variants in the immediate neighborhood of j at comparative rate $\zeta \in [0, 1)$ and be major variant-independent: i.e., we assumed

Shedding:
$$\zeta_{j\ell} = \begin{cases} 1 & \text{if } \ell = j \\ \zeta & \text{if } \ell \text{ differs from } j \text{ by one allele} \\ 0 & \text{otherwise} \end{cases}$$
 (6)

Finally, in this paper we will not investigate any seasonal effects, which is equivalent to setting $\delta_{\text{season}} = 0$ in Eq. A.10, and using this setting in all our simulation.

The model itself can be accessed at Github, where instructions are available for launching and using our SEIVAgent application.




Figure 2: A. The dashboard of our Java Runtime-Alterable-Model Platform (RAMP) SEIVD (S=susceptibles, E=exposed, I=infectious, V=immune, D=dead) individualbased model (IBM) and simulations obtained using the parameters values depicted in the slider windows (also see Table 2). The top left window of this dashboard contains information on the final state of the population (in this case S = 3898 and D = 143 in a population of $N_0 = 10,000$), the bottom left bar graph of dashboard panel is the final values of E, I, V and D at epidemic cessation at time t = 166 (days) or the simulation run time, whichever comes first. Dashboard also shows a graph of incidence (purple: selected using colored buttons below the graph). The bottom ribbon of the dash board has a series of radio buttons that respectively open a Log, a JavaScript (JS), and a Scripting (S) window, Line and Bar graph windows (for multivariant runs), as well as windows for controlling vaccination strategies (V), listing realtime agent information (A), pathogen parameter values (P), monitoring probability computations (Intern), coding and controlling runtime alternative operations (Op), and three runtime buttons (Reset, Step, Run). B. Graphs of prevalence and cumulative deaths (cut out from main panel when only the red and black buttons are on) and C. daily deaths (crimson button) are pasted below the dashboard.

Getz et al.

Getz et al.

3 Illustrative Examples

³⁰⁴ 3.1 Single variant simulations

³⁰⁵ Parameter values and baseline run

The first variable that needs to be determined is the unit of time we use for 306 our simulations because all process rate parameters are scaled by its selection. 307 Since the time resolution of empirical COVID-19 incidence and mortality data is 308 daily, we selected our unit of time t to be days. Additionally, based on various 309 sources including a metapopulation study of COVID-19 parameter estimates 310 [39], we set the latent and infectious periods to be 4 and 7 days respectively. 311 Basic SEIR epidemiological models do not separate out the processes of contact 312 and transmission-per-contact, so we had some leeway on what values to choose 313 for contact rates and transmission rates per contact because it is the value of 314 the product of these that is important in determining the reproductive value, 315 commonly referred to as " R_0 " for COVID-19. Hussein et al.'s [39] meta analysis 316 of COVID-19 zeroed in on $R_0 = 3.14$ as a mean value across a range of studies 317 (95% confidence interval [2.69, 3.59]). By setting our baseline contact rate and 318 transmission parameters to be $\kappa_0 = 3$ and $\beta = 0.3$, we estimated the value of 319 R_0 in our model to be approximately $R_0 = 3.1$. These and the remaining values 320 of the parameters used in our simulations are summarized in Table 2. 321

322 Adaptive contact rate

None of the major outbreaks of COVID-19 around the world followed a classic 323 "rise-and-fall" incidence curve because of social distancing and other measures 324 taken to mitigate transmission once it had been determined that a full-blown 325 outbreak was underway. These measures waxed and waned with government 326 regulations and the perception that the outbreak was respectively under or out 321 of control. This, in turn, resulted in incidence profiles that rose and fell multi-328 ple times (i.e., so-called waves) as these measures waxed and waned. Thus, it 329 is not possible to replicate the incidence curves of any of the country/regional 330 epidemics without characterizing the social distance and subsequent social re-331 laxation measures driving their rise and fall [15]. 332

In a general way, we can capture the gestalt effects of this kind of social 333 behavior by assuming the contact rate $\kappa(t)$ is influenced by current or recent 334 prevalence levels, where current prevalence is given by the ratio of the number 335 of infected individuals $N_{\rm I}(t)$ to current population size $N(t) - N_{\rm D}(t)$. Thus, in 336 the various scenarios present below, we assume an adaptive response rate that 337 has a maximum value κ_0 when I(t) = 0 and is reduced to half this value, as 338 a declining sigmoidal curve specified in Eq. A.7, when $\frac{N_{\rm I}(t)}{N(t)-N_{\rm D}(t)} = p_{\rm I}^{\rm half}$. If 339 we simulate the first year of an epidemic using our basic parameters (Table 2; 340 also see parameter panel in Fig. 2) and adaptive contact half-max parameters 341 for the cases $p_{\scriptscriptstyle \rm I}^{\rm half}=0.01$ and 0.02 (i.e., 1% and 2% prevalence respectively), we 342 obtain the percent of susceptibles (uninfected) and cumulative deaths by day 343 365 provided in Table 3. 344

For purposes of comparison, we also provide in Table 3 the percent of susceptible individuals and percent of deaths due to COVID-19 one year after the day

Submitted on August 12, 2021

Getz et al.

Parameter	Symbol	Value	Source/Comment
single-variant simulations			
Time unit	t	daily	empirical data is daily
Nominal pop size	N_0	$10^{5} - 10^{7}$	see Section 3.1^{\ddagger}
Effective contact rate ^{\dagger}	κ_0	3 per day	implies $R_0 \approx 3.1^+$
Transmission	β	0.3	implies $R_0 \approx 3.1^+$
Latent Period	$\sigma_{ m E}$	4 days	median time in \mathbf{E}^{\P}
Infectious period	$\sigma_{ m I}$	$7 \mathrm{~days}$	median time in I^{\S}
Immunity half-life	t^{half}	1/2 to 1 year [±]	per run specs.
Disease-induced mort.**	p_{lpha}	2% of cases *	mortality rate is $\alpha^{\#}$
Adaptive contact param.	$p_{ m I}^{ m half}$	0,0.002,0.05	decreasing $\kappa(I)^{*\dagger}$
Seasonal fluctuation param.	$\delta_{ m season}$	0	seasons ignored $^{*+}$
Multi-variant simulations	(single-variant par	ameter values used	where applicable)
Mutation factor ^{*‡}	μ	$0.001^{*\#}$	See Eq. $A.13$
variant number	$j = 0,, 2^{J-1}$	$J \ {\rm is} \ 0 \ {\rm to} \ 7$	i.e., 2 to 128 variants
Cross immunity	c_{mj}	0.8	Eqns. 1, 2
Pathogen shedding	$ar{\zeta}_{j\ell}$	$0.001^{*\#}$	See Eq. A.9
Environmental persistence	$ar\eta_j$	1 for all j	See Eq. A.10
Transmission	$ar{eta}_j$	$\delta_{\beta} \in [0, 0.2]$	See Eq. 4
Within-host replication rate	λ_j	1 for all j	See Eq. A.13
Disease-induced mort.**	p_{lpha_j}	0.02	See Eq. 5

Table 2: Parameter values used to simulate single and multivariant outbreaks

 $^{\ddagger} In$ particular see discussion headed: Population size and demographic stochasticity

⁺See Eq. A.26 [†]See Eq. A.7

¶Reciprocal of γ in continuous time computation of R_0 per Eq. A.26

[§]Reciprocal of ρ in continuous time computation of R_0 per Eq. A.26

[±]Based on statement in [23]: "... studies of animal coronaviruses antibody titers ... waned substantially 1 year after initial infection ... and many could be reinfected and shed virus ..." ||See Eq. A.6: note w(t) switches from 1 to 0 as immunity goes from complete to absent

*Value at start of the pandemic, but typically lower later in most regional epidemics #This is "virulence" parameter of continuous-time SEIR models

**If $\alpha \ll 1$ then $p_{\alpha_i} = 1 - e^{-\alpha} \approx \alpha$

*[†]See Eq. A.7. Setting $p_{\rm I}^{\rm half} = 0$ implements $\kappa(0) = \kappa_0$, though $\kappa(t) \to \kappa_0$ as $p_{\rm I}^{\rm half} \to \infty$

*+Implies values of k and θ in Eq. A.10 are irrelevant

 $*^{\ddagger}$ variant independent—variant dependence requires more elaborate model

 $^{\ast\#}$ Quantifies the mutation rate observed at a population rather than within-cell replication level

**If $\alpha_j << 1$ then $p_{\alpha_j} = 1 - e^{-\alpha_j} \approx \alpha_j$

on which more than 10 cases of COVID-19 were recorded to occur in the USA,

³⁴⁸ Italy and Czechia (extracted from data provide at Worldometer). Since these

data are known to be substantially under reported for both cumulative preva-

Submitted or	August	12,	2021
--------------	--------	-----	------

lence [40] and deaths [41], we felt that $p_{\rm I}^{\rm half} = 0.01$ (i.e. 1% prevalence) provides a reasonable ballpark value for an adaptive contact rate half-max parameter for our various illustrations provided in below.

Table 3: Basic runs with one million individuals (N = 1,000,000) using two different half-max adaptive contact parameter values $p_{\rm I}^{\rm half}$ compared with listed countries^{*}

	$p_{ m I}^{ m half}$		USA		Czechia
	1%	2%	(value	s under r	$(eported)^{\ddagger}$
Uninfected at day 365 COVID-19 deaths by day 365	$82\% \\ 0.34\%$	71% 0.55%	$93\% \\ 0.12\%$	$95\% \\ 0.17\%$	$\frac{88\%}{0.21\%}$

*Data from Worldometer

 $^{\dagger}\mathrm{One}$ year after the first 10 recorded cases in the countries concerned

[‡]Substantial under reporting occurs for both cases [40] and deaths [41].

³⁵³ Population size and demographic stochasticity

Deterministic SIR/SEIR and related models will always produce an epidemic 354 whenever the parameters ensure that $R_0 > 1$ [2,34]. Since these models do not 355 include the demographic stochastic effects associated with finite populations, 356 they are unable to capture the phenomenon of stochastic extinction of the epi-357 demic before it gets going when a single infected individual is introduced into 358 an otherwise infected population (with regard to the pathogen in question; see 359 discussion in SOF A.4). In such models, results are either cited using percent-360 ages or numbers per thousand or per hundred thousand individuals and the 361 actual population size is not regarded as a factor. Population size, however, is 362 a factor in determining the absolute size of an epidemic once it gets started and 363 deterministic models provided a robust assessment of the course of the epidemic 364 in populations consisting of millions of individuals (other factors, such as spatial 365 or contact network structure play a more important role than size per se [5-7]). 366 To get a sense of the effects of demographic stochasticity on populations of 367 different sizes in our simulations, we compared the prevalence, incidence, and 368 cumulative deaths obtained for single runs (runtime seed = 1) of a basic adaptive 369 contact rate scenario (basic parameters plus $p_{\rm I}^{\rm half} = 0.01$) for cases where the 370 initial population sizes where $N_0 = 10,000, 100,000$ and 1,000,000 (Fig. 3A-C). 371 We also compared the mean prevalence plus/minus 1 standard deviation (sd) for 372 100 runs (runtime seeds ranging from 0 to 99) for the two cases $N_0 = 10,000$ and 373 100,000 over both the first year (Fig. 3D & E) and the first 100 day (Fig. 3F). 374 The results depicted in Fig. 3 can be encapsulated in the following four 375

³⁷⁶ well-established principles:

1. The initial phase of an outbreak is independent of population size and establishment of an epidemic depends solely on the value of R_0 (SOF, Append A.4). Thus, as we see in Fig. 3F, the first 50 days of the mean prevalence for the simulations of the cases N = 10,000 and N = 100,000

Submitted	on	August	12.	2021

- are virtually identical, only departing from one another from around day50 onwards.
- Beyond the initial phase, stochastic fluctuations are more evident in smaller than larger populations (compare Figs. 3A, B and C)
- Ultimate prevalence levels, aside from stochastic fluctuations are independent of population size. Thus, for example, we see that prevalence maxes out at round 0.6% in all three cases (dotted line) across a range of two orders of magnitude in population size.
- 4. Mean population prevalence will always max out at lower levels than the prevalence reached in actual runs (viz. the max exceeds 7% individual runs in Fig. 3A-C while it is between 4% and 5% for the red curves in Fig. 3D&E) because the mean values take into account the fact a proportion $1/R_0$ of the runs go extinct within the first several weeks [42].




Figure 3: A-C: Plots of percentage prevalence (red), incidence (purple) and cumulative dead (black) for 365 day simulations using the parameter values given in Table 1 with the adaptive contact rate parameter $p_{\rm I}^{\rm half} = 0.01$ (see Eq. A.7) and N = 10,000, N = 100,000 and N = 1,000,000 respectively. **D-E**: Plots of mean percentage prevalence (red) over the first year plus (green) minus (blue) 1 standard deviation over 100 runs (runtime seeds going from 0 to 99) for the cases N = 10,000 and N = 100,000respectively. **F**: Plots of the actual prevalence (number of individuals) for the first 100 days for the cases N = 10,000 (red) and N = 100,000 (black).

³⁹⁴ **3.2** Multivariant simulations

We carried out a series of multivariant simulations with J = 4 (i.e., 16 variants can emerge) in a population of size N = 50,000. We compared the scenarios of cascading cross immunity with c = 0.8 (Eq. 1) and transmissions rates the same for all variants (Fig. 4A) with the same cascading cross immunity as in Fig. 4A,

Submitted on August 12, 2021	Getz et al.

³⁹⁹ but now we allowed transmission to increase by 20% for each mutation difference ⁴⁰⁰ between variant j and variant 0 ((Eq. 1; $\beta_j = 0.3, j = 0, ..., 15, \delta_\beta = 0.2$ and ⁴⁰¹ $\beta_j, j = 1, ..., 15$, determined using Eq. 4). Finally, we compared the scenario ⁴⁰² of cascading cross immunity with that of escaping cross immunity for the case ⁴⁰³ c = 0.8 (Eq. 2), and obtained the results provide in Fig. 4C. The severity of ⁴⁰⁴ each scenario is encapsulated in the total death statistic over the course of the ⁴⁰⁵ two-year simulation.




Figure 4: Total daily incidence (Δ I+: purple) and variant-specific prevalence (I: red) for a 16-variant epidemic in a population of size N = 50,000 (for other parameter values see Table 2) are plotted over a two-year period for the three cases: **A.** cascade cross immunity $\delta_{\beta} = 0.0$ (i.e., all $\beta_j = 0.3, j = 0, ..., 15$) and $\delta_{\beta} = 0.2$ (i.e., $\beta_0 = 0.3$, $\beta_{15} = 0.622$ and $\beta_j, j = 1, ..., 14$, determined using Eq. 4). Variant number and corresponding binary representation as labeled in red for dominant or co-dominant variants (incidence at some point > 50 individuals per day) and gray for minor variants (incidence always < 50 over the two-year simulation). The order of emergence of dominant or co-dominant variants is labeled in green. Note that each panel has its own vertical scale but all plots are over 730 days (even in cases where the horizontal axis label go to 750).

Submitted on August 12, 2021

Our primary observations comparing the results plotted in Fig. 4A-C and
other runs (not shown here) of the same scenarios using different runtime seeds,
are the following:

In all three cases the initial variant, by construction, is $0 \equiv (0, 0, 0, 0)$. In 409 our three scenarios, this variant was followed by chance by the emergence 410 of variant $8 \equiv (1, 0, 0, 0)$, but this is common to all three scenarios because 411 they use the same sequence of pseudo random numbers in their simula-412 tions. Using different runtime seeds, however, leads to other variants than 413 8 emerging to replace variant 0. Thus, the mutant identity (i.e., its bi-414 nary representation) of the variant to first emerge is somewhat random, 415 but it is going to be influenced by having different transmission values for 416 each variant (scenarios B and C), as well as the possibility of an idealized 417 escape mutation (scenario C). 418

• We expect variants that have an idealized escape mutation to emerge early, as is the case in scenario C in which variants 8-15 have the idealized escape mutation. In particular, in Fig. 4C, we see that the second to fourth variants to emerge all have the idealized escape mutation (i.e., variant 8 then 14 and then 15), and finally variant $6 \equiv (0, 1, 1, 0)$ emerges because of the cross-immunity between all variants with the idealized escape mutation finally comes into play.

• When $\delta > 0$, the variants with the higher values of β come to dominate, 426 though they take time to emerge. In our cascading cross-immunity case 427 with $\delta_{\beta} = 0.2$, the most transmissible of these (variant $15 \equiv (1, 1, 1, 1)$) 428 had yet to emerge within the simulated 2-year period. The existence of 429 the idealized escape mutation, however, does facilitate the emergence of 430 variant 15 at the beginning of the second year (Fig. 4C). Another run 431 of this scenario (runtime seed=1; results not shown here) has variant 15 432 emerging very early (around day 120). Further, due to the effects of cross 433 immunity, this variant was replaced by variant $11 \equiv (1, 0, 1, 1)$ around days 450-500. Variant 15, however, as result of waning and cross-immunity 435 affects, reemerges again around day 600, with variant 11 declining over the 436 last three months of the second year. 437

438 3.3 Vaccination rollout

439 Single valency vaccinations

As illustrations of potential issues associated with the design and implementation of vaccination programs, we first considered vaccinating individuals in a population of 100,000 subject to an epidemic involving a single variant of the pathogen. We note that in a population of N = 100,000 individuals, a vaccination rate of v(t) = 0.001 involves vaccinating an average of 100 individuals per day with daily variation following a binomial distribution (i.e., a standard deviation of just under 10 individuals per day).

Rollout of our vaccination program began on day 366 after the start of the outbreak and ran for two years beyond that to day 1100 (Fig. 5). Such scenarios place us within the context of the COVID-19 epidemic since vaccinations were

Submitted on August 12, 2021

only available from around the second year onwards. In our first two scenarios, 450 we selected individuals respectively at rates 0.1% (v = 0.001) and 0.2% (v =451 0.002) of the population each day (Fig. 5A & B). Only individuals that had not 452 been previously vaccinated were selected, but selection was otherwise random. 453 Additionally, we simulated a 16-variant scenario in which individuals were 454 vaccinated at against variant 0 at rate v = 0.002 (Fig. 5C). Again, individuals 455 were selected at random from the set of those that had not been previously 456 vaccinated. By vaccinating individuals against variant 0, some immunity was 457 conferred against variants 1-7 through cross-immunity relationships according 458 459 to the Escaping C case with cross-immunity parameter c = 0.8 (Eqn. 2). In this scenario, variants 8-15 contain the idealized escape mutation. 460

Our focal question with regard to the first two scenarios was: What vaccina-461 tion level is needed to extinguish the epidemic in the population encompassed 462 by the vaccination rollouts for the populations concerned? From these two sim-463 ulations (Fig. 5A & B) we see that vaccination rate v(t) = 0.001 was insufficient 464 to eliminate the pathogen from the population, while v(t) = 0.002 was able 465 to eliminate the pathogen within 10 months from the start of the vaccination 466 rollout. Further, in the first of these simulations (Fig. 5A), we see a resurgence 467 of incidence in year three, which implies that the effects of waning immunity in 468 this case are essentially "outrunning the vaccination rate." 469

Our focal question with regard to a comparison of scenarios two and three 470 (Fig. 5B & C) was: Does the vaccination rate v(t) = 0.002, which was able to 471 exterminating the outbreak in the 1-variant case, remain able to exterminate the 472 outbreak in the 16-variant case when an idealized escape mutation is involved? 473 The answer to this question from the observed incidence curve (Fig. 5C) is a 474 resounding no. In fact, the total death rate over the three year period rose from 475 0.13% of the population (1336 individuals) to 0.42% of the population (4,235) 476 individuals). 477

478 Adaptive bivalent vaccinations

With the emergence of new variants, the possibility exists to modify vaccines 479 to contain or induce the production of antigens that directly target the variant 480 in question (i.e., rather than through cross-immunity that arises when a related 481 variant is the direct target) [28]. Further, it is possible for vaccines to be mul-482 tivalent in terms of directly targeting more than one variant at time [28]. In 483 our third vaccination scenario, a univalent vaccine applied at a rate v = 0.002484 failed to bring a multivariant epidemic under control. Thus we were motivated 485 to explore a scenario to see what would happen with a bivalent vaccine that 486 was implemented adaptively in the sense of its two valencies following the two 487 dominant variants. 488

In the specific vaccination rollout program that we employed in our fourth simulation, we did not account for logistical, production, and variant monitoring constraints. Such constraints, of course, exist and vary across locations and populations: in real applications, they need to be taken into account. The program we employed assumes that we are able to alter the valency of the vaccination used every 15 days, based on an ability to identify the two variants that are most prevalent at each of these successive 15-day-apart observation




Figure 5: Incidence (ΔI^+ : purple) is plotted over 3 years for the baseline run (parameters given in Table 1 with N = 100,000) for the cases where vaccination rates v(t) (indicated by blue lines) are applied during the second and third years only to individuals not previously vaccinated but otherwise selected at random (for clarification, the average number of individuals vaccinated each day is 100v(t)% with variation following a binomial distribution). Our first two simulations involve vaccinated, but otherwise chosen at random. Our second two simulations involve vaccinated, but otherwise chosen at random. Our second two simulations involve vaccination rollout programs in a 16-variant epidemic, both at vaccination rates v(t) = 0.002, involving **C**. individuals not previously vaccinated and **D**. a bivalent adaptive vaccination program in which previously vaccinated individuals could be vaccinated again with a new valency vaccine, as described in the text.

⁴⁹⁶ points (from day 365 to day 1085, which is the start of the last 15 day period ⁴⁹⁷ ending just prior to the start of day 1100). If only one variant had an incidence ⁴⁹⁸ exceeding 9 individuals on an observation day, then the vaccination applied over ⁴⁹⁹ the next 15 day interval was monovalent for the dominant variant, otherwise ⁵⁰⁰ it was bivalent for the two variants that had the highest incidence on that ⁵⁰¹ observation day.

As with the non-adaptive vaccination rollouts, individuals were selected at 502 random from a pool that had previously not been vaccinated with the partic-503 ular valency-specific vaccine (either bivalent or monovalent). However, in the 504 bivalent vaccine case, if an individual had previously been vaccinated to only 505 one of the two variants defining the latest vaccine, then these individuals were 506 incorporated into the vaccination pool from which individuals were randomly 507 selected for vaccination. If such individuals were selected then the start of the 508 waning time relating to the previous vaccination was reset to start anew. Thus, 509 with this program, it is possible for individuals to be vaccinated more than once. 510 The results of this simulation are depicted in Fig. 5D, where we see that 511 this vaccination program is much more effective in preventing deaths than the 512

Submitted on August 12, 2021

Getz et al.

monovalent variant 0 program applied to the same 16-variant epidemic at the 513 same vaccination rate Fig. 5C (total deaths are 4,235 in the former versus 2145 514 in the latter case). The valencies of the vaccine applied during each new 15 515 day period are listed in Table 4. We note that the monovalent case involves 516 considerably fewer vaccinations because of the "no revaccination with the same 517 vaccine" restriction in our rollout program. In particular, over two years of 518 vaccinating at a 0.2% rate per day, all individual are vaccinated in the case of 519 Fig. 5C by day 859 while, in the case of Fig. 5, revaccinations kept occurring 520 as individual that have not previously been vaccinated to one of the focal vari-521 522 ants was revaccinated. Even in this adaptive rollout, however, the epidemic was only substantially lowered rather than completely extinguish. The latter event 523 for the set of parameters used in our simulation requires a somewhat higher 524 vaccination rate than 0.2% per day; or, perhaps it requires lower rates of wan-525 ing immunity, higher cross-immunity rates, or the lack of an idealized escape 526 mutation. All of these effects can be demonstrated through the selection of ap-527 propriate parameter values, but the specifics are only relevant when the model 528 is applied in a real world situation. 529

Table 4: Valency of adaptive vaccination over the interval [365, 1100]

Time	Valency
[365, 470)	(9,14)
$[470, 530) \\ [530, 680)$	(13,14) (13,15)
[680, 740) [740, 905)	(15) (10,15)
[905, 1025)	(10, 12)
$[1025, 1070) \\ [1070, 1100)$	(12,15) (15)

530 4 Discussion

The amount of structure and data needed in complex biological systems' mod-531 els, depends on the questions that these models have been formulated to ad-532 dress [13,14]. In this paper, we steered away from making specific predictions-533 because universal solutions are not always locally applicable. Rather, we focused 534 on gaining insights into incidence patterns that can be expected when contacts 535 are adaptive rather than fixed, multiple variants may emerge (typically sequen-536 tially over time), and open versus adaptive uni- and multivalent vaccination 537 programs are implemented to try to eliminate local pandemics. Analyses that 538 incorporate more complexity in the hopes of attaining greater realism, such as 539 adding heterogeneity related to age and spatial structures, as well as behavioral 540 and social groups, require data that is specific to a local population (town, city, 541 county, or small country, etc.) Such elaborations are only worth incorporating 542 when the study relates to a real world system supported by adequate data (the 543

Submitted on August 12, 2021

⁵⁴⁴ latter related to the complexity of the question that needs to be addressed, as ⁵⁴⁵ discussed elsewhere [13]).

Of course, additional structure can be added to address questions of general 546 interest. One obvious issue relating to our study would be to obtain a better 547 understanding of the role informational delays may play in producing the type of 548 incidence waves that have observed over the course of the COVID-19 pandemic 549 (and as we have modeled in [43]). Such delays would lead to contact rates 550 containing a time-lag rather than depending only on current prevalence levels. 551 We might also spend more time deconstructing the relative importance of such 552 time delays versus the emergence of more transmissible variants in accounting 553 for these waves. 554

Beyond gaining a deeper understanding of some of the mechanisms responsi-555 ble for the incidence patterns observed among local epidemics of the COVID-19 556 pandemic, a second and primary purpose of our paper is to present our M-557 SEIR RAMP as a platform that others may use to address issues of concern 558 to them in formulating policies to manage local COVID-19 epidemics. This 559 also has the advantage of providing an exemplar of our novel RAMP (runtime 560 alterable model platform) concept and the methods we used to construct it. 561 At this time, the primary value of our M-SEIR RAMP itself may be in testing 562 various vaccination strategies as they relate to variant emergence [44]. Clearly, 563 such applications would require more specific variant-related information on 564 the comparative transmissibility β_j , virulence α_j , shedding (ζ_{jm}) , environmen-565 tal persistence $(\bar{\eta}_i)$, and within host replication rates (λ_i) of newly emerging 566 variants. 567

Equally important, though, in evaluating the impacts of vaccination strate-568 gies on local epidemics is obtaining variant-specific immunity and cross-immunity 569 data. This includes waning rates, which we have not made variant specific. Our 570 model, however, could be generalized to include variant specific waning rates 571 represented by the parameter t_i^{half} (Eq. A.6). It also includes information for 572 characterization of the elements $c_{i\ell}$ of the cross immunity matrix C (i.e., a 573 generalization that renders Eq. 1redundant). Models are sorely needed to ex-574 plore multivariant dynamics, particularly the epidemiological properties regard-575 ing shedding, environmental persistence, transmission, mutation, and within-576 host replication rates. These processes, acting together, determine the relative 577 success of different variants and their actual impact on the severity of epidemics 578 and the nature of vaccination programs needed to suppress them. 579

Making our model both location and variant specific could be undertaken 580 using methods, such as Appropriate Complexity Modeling [13, 14], designed to 581 enhance the relevancy of models. Further, in some cases it may be useful to 582 add spatial or age-structure information to our M-SEIR or include a contact 583 network [7], which itself may contain spatial or refined class category (e.g. age 584 or work categories) information. In addition, our current implementation repre-585 sents variant differences in terms of J loci with two alleles (denoted by 0 and 1 586 respectively) at each locus. A more realistic representation of the genetic basis 587 of variant differences may involve genetic representations in which several alleles 588 are possible at each locus. Further, the loci themselves may represent relevant 589 molecular structures such as epitopes. 590

591

An advantage of our RAMP design features is that they provide a framework

Submitted on August 12, 2021

Getz et al.

for elaborating or simplifying model details in the pursuit of different questions 592 at various points in a pandemic. For example, suppose we are interested in 593 pursuing inferences regarding the drivers of variant evolution at a various stages 594 of the pandemic. We may first want to address questions relating to pandemic 595 behaviour, driven by mutations that increase transmissibility. This is what 596 actually happened with the appearance of the D614G and the alpha variants. 597 A year or so into the pandemic, however, we may then want to explore processes 598 that give rise to immunity-escaping variants. This, again, is what happened in 599 reality. Our RAMP formulation gives us the flexibility to change the model part 600 601 way through a pandemic. In particular, we can then test which among a set of alternative reinfection process is most likely to produce an escape mutation once 602 reinfection begins to occur on a substantial scale. By configuring model drivers 603 so that we first have a relatively simple evolutionary process and then switch to 604 more complex evolutionary processes, our RAMP design facilitates comparing 605 several competing explanations of observed patterns of variant emergence at 606 different stages of a pandemic. 607

Although cross-immunity and immune waning are entangled in our immu-608 nity modifier functions (i.e., ϕ_{ij} ; see Eq. A.8), cross-neutralization data can be 609 used to estimate the cross and waning immunity parameters using appropriate 610 methods [45]. Such data are becoming more widely available through the ap-611 plication of improved serological and genetic methods [24, 46, 47]. Variant and 612 cross neutralizing studies bring up a much neglected issue, which is the effect of 613 dose (number of pathogens involved in the initial infection, also know as viral 614 load) on the severity of the infection. Further, dose affects both the probability 615 of host invasion (in the context of transmission), as well as mutational rates 616 once host invasion has occurred. Effective dose differs from the questions of 617 the number of vaccine doses (typically one versus two) versus the antigen or 618 virus-like particle load in each dose [48]. In the context of vaccination, both 619 these issues and the technology used to produce the vaccine [28] may well have 620 an impact on waning immunity rates and cross-immunity values. Thus, the 621 parameter values used in the model should ultimately be vaccine specific, once 622 vaccine-specific waning data have been obtained. 623

In the coming years, as we obtain more information on the nature of waning 624 and cross immunity to different variants of SARS-CoV-2, not to mention the 625 vaccines as well, it will become more apparent to us whether or not COVID-19 626 will settle into global endemicity [32, 49] and require periodic vaccinations to 627 combat new variants, as they arise over time. If this is the case, then constant 628 vigilance and a well-designed vaccination program with respect to vaccinating 629 the young and implementing booster vaccinations with appropriate variant va-630 lency will become the order of the day. Additionally, we anticipate extending 631 our M-SEIR RAMP to include runtime alterable modules (RAMs) designed to 632 compute the optimal time to administer vaccine booster shots of the same or 633 different variant valencies. Implementation of these RAMs can play a decisive 634 role in the rational design of effective and efficient COVID-19 vaccination pro-635 grams worldwide. The need for efficacy is made apparent from the fact that 636 our simulations suggest that it may be harder than currently anticipated to 637 eliminate COVID-19 using non-adaptive vaccination programs. 638

639

Finally, our M-SEIR RAMP, with its RAMs, driver scripts and ability to

Submitted on August 12, 2021

Getz et al.

⁶⁴⁰ be integrated with R and other software platforms and a JavaScript simulation
⁶⁴¹ driver window, provides the first example of a new concept in model implemen⁶⁴² tation that facilitates model sharing and easy modification by users other than
⁶⁴³ the original developers. We believe such platforms can come to play an impor⁶⁴⁴ tant role not only in disease modeling, but in all fields of research that rely on
⁶⁴⁵ models for comprehensive analyses of the behavior of systems of interest.

646 Acknowledgements and Funding Sources

⁶⁴⁷ This work was funded in part by NSF Grant 2032264 (PI: WMG).

648 References

- [1] Kermack WO, McKendrick AG. A contribution to the mathematical theory
 of epidemics. Proceedings of the royal society of london Series A, Containing
 papers of a mathematical and physical character. 1927;115(772):700-721.
- [2] Hethcote HW. The mathematics of infectious diseases. SIAM Review.
 2000;42(4):599–653.
- [3] Koelle K, Cobey S, Grenfell B, Pascual M. Epochal evolution shapes the
 phylodynamics of interpandemic influenza A (H3N2) in humans. Science.
 2006;314(5807):1898–1903.
- [4] Gilchrist MA, Sasaki A. Modeling host-parasite coevolution: a nested
 approach based on mechanistic models. Journal of Theoretical Biology.
 2002;218(3):289–308.
- [5] Balcan D, Gonçalves B, Hu H, Ramasco JJ, Colizza V, Vespignani A.
 Modeling the spatial spread of infectious diseases: The GLobal Epidemic
 and Mobility computational model. Journal of computational science.
 2010;1(3):132–145.
- [6] Keeling MJ. The effects of local spatial structure on epidemiological inva sions. Proceedings of the Royal Society of London B: Biological Sciences.
 1999;266(1421):859–867.
- [7] Keeling MJ, Eames KT. Networks and epidemic models. Journal of the
 Royal Society Interface. 2005;2(4):295–307.
- [8] Bauer AL, Beauchemin CA, Perelson AS. Agent-based modeling of host pathogen systems: The successes and challenges. Information sciences.
 2009;179(10):1379–1389.
- [9] Cuevas E. An agent-based model to evaluate the COVID-19 transmission risks in facilities. Computers in biology and medicine. 2020;121:103827.
- [10] Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. A
 dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic
 epidemiology. Nature microbiology. 2020;5(11):1403–1407.
- [11] Koopman JS, Simon CP, Getz WM, Salter R. Modeling the population
 effects of escape mutations in SARS-CoV-2 to guide vaccination strategies.
 Epidemics. 2021;p. 100484.
- [12] Aslaner H, Aslaner HA, Gökçek MB, Benli AR, Yıldız O. The effect of
 chronic diseases, age and gender on morbidity and mortality of covid-19
 infection. Iranian Journal of Public Health. 2021;50(4):721.

[13] Getz WM, Salter R, Mgbara W. Adequacy of SEIR models when epidemics
 have spatial structure: Ebola in Sierra Leone. Philosophical Transactions
 of the Royal Society B. 2019;374(1775):20180282.

- Larsen LG, Eppinga MB, Passalacqua P, Getz WM, Rose KA, Liang
 M. Appropriate complexity landscape modeling. Earth-science reviews.
 2016:160:111-130.
- [15] Getz WM, Salter R, Luisa Vissat L, Horvitz N. A versatile web app for
 identifying the drivers of COVID-19 epidemics. Journal of Translational
 Medicine. 2021;19(1):1–20.
- [16] Rahimi I, Chen F, Gandomi AH. A review on COVID-19 forecasting mod els. Neural Computing and Applications. 2021;p. 1–11.
- [17] Chretien JP, George D, Shaman J, Chitale RA, McKenzie FE. In fluenza forecasting in human populations: a scoping review. PloS one.
 2014;9(4):e94130.
- [18] Getz WM, Gonzalez JP, Salter R, Bangura J, Carlson C, Coomber M,
 et al. Tactics and strategies for managing Ebola outbreaks and the salience
 of immunization. Computational and mathematical methods in medicine.
 2015;2015.
- [19] Chen PZ, Bobrovitz N, Premji Z, Koopmans M, Fisman DN, Gu FX. Het erogeneity in transmissibility and shedding SARS-CoV-2 via droplets and
 aerosols. eLife. 2021 apr;10:e65774. Available from: https://doi.org/
 10.7554/eLife.65774.
- [20] van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble
 A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV2 as Compared with SARS-CoV-1. New England Journal of Medicine.
 2020;382(16):1564–1567. Available from: https://doi.org/10.1056/
 NEJMc2004973.
- [21] Maginnis MS. Virus-receptor interactions: the key to cellular invasion.
 Journal of molecular biology. 2018;430(17):2590-2611.
- [22] Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K,
 Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant
 of concern 202012/1: matched cohort study. bmj. 2021;372.
- [23] Sariol A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity. 2020;.
- [24] Eguia RT, Crawford KH, Stevens-Ayers T, Kelnhofer-Millevolte L,
 Greninger AL, Englund JA, et al. A human coronavirus evolves antigeni cally to escape antibody immunity. PLoS pathogens. 2021;17(4):e1009453.
- [25] Alizon S, Luciani F, Regoes RR. Epidemiological and clinical consequences of within-host evolution. Trends in microbiology. 2011;19(1):24–32.
- [26] Fenichel EP, Castillo-Chavez C, Ceddia MG, Chowell G, Parra PAG, Hick ling GJ, et al. Adaptive human behavior in epidemiological models. Pro ceedings of the National Academy of Sciences. 2011;108(15):6306–6311.

- ⁷²⁵ [27] Gozzi N, Bajardi P, Perra N. The importance of non-pharmaceutical in-⁷²⁶ terventions during the COVID-19 vaccine rollout. medRxiv. 2021;Avail-
- able from: https://www.medrxiv.org/content/early/2021/01/09/
- 728 2021.01.09.21249480.
- [28] Kumar A, Dowling WE, Román RG, Chaudhari A, Gurry C, Le TT, et al.
 Status Report on COVID-19 Vaccines Development. Current Infectious
 Disease Reports. 2021;23(6):1–12.
- [29] Jefferies JM, Clarke SC, Webb JS, Kraaijeveld AR. Risk of red queen
 dynamics in pneumococcal vaccine strategy. Trends in microbiology.
 2011;19(8):377–381.
- [30] Willem L, Verelst F, Bilcke J, Hens N, Beutels P. Lessons from a decade of
 individual-based models for infectious disease transmission: a systematic
 review (2006-2015). BMC infectious diseases. 2017;17(1):612.
- [31] Chowell G, Sattenspiel L, Bansal S, Viboud C. Mathematical models to
 characterize early epidemic growth: A review. Physics of life reviews.
 2016;18:66–97.
- [32] Lavine JS, Bjornstad ON, Antia R. Immunological characteristics govern
 the transition of COVID-19 to endemicity. Science. 2021;371(6530):741–
 745.
- [33] Koyama T, Weeraratne D, Snowdon JL, Parida L. Emergence of drift vari ants that may affect COVID-19 vaccine development and antibody treat ment. Pathogens. 2020;9(5):324.
- [34] Getz WM, Lloyd-Smith JO. Basic methods for modeling the invasion and
 spread of contagious diseases. DIMACS Series in Discrete Mathematics
 and Theoretical Computer Science. 2006;71:87.
- [35] McCallum H, Barlow N, Hone J. How should pathogen transmission be
 modelled? Trends in ecology & amp; evolution. 2001;16(6):295–300.
- [36] Anderson RM, May RM, et al. Coevolution of hosts and parasites. Para sitology. 1982;85(Pt 2):411-426.
- ⁷⁵⁴ [37] Getz WM, Salter R, Muellerklein O, Yoon HS, Tallam K. Modeling epi demics: A primer and Numerus Model Builder implementation. Epidemics.
 2018;25:9–19.
- ⁷⁵⁷ [38] Getz WM, Salter R, Lyons AJ, Sippl-Swezey N. Panmictic and clonal
 ⁷⁵⁸ evolution on a single patchy resource produces polymorphic foraging guilds.
 ⁷⁵⁹ PloS one. 2015;10(8):e0133732.
- [39] Hussein M, Toraih E, Elshazli R, Fawzy M, Houghton A, Tatum D, et al.
 Meta-analysis on serial intervals and reproductive rates for SARS-CoV-2.
 Annals of surgery. 2021;273(3):416–423.

- [40] Lau H, Khosrawipour T, Kocbach P, Ichii H, Bania J, Khosrawipour V. Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters. Pulmonology. 2021;27(2):110–115.
- [41] Karlinsky A, Kobak D. Tracking excess mortality across countries dur ing the COVID-19 pandemic with the World Mortality Dataset. eLife.
 2021;10:e69336.
- [42] Hartfield M, Alizon S. Introducing the outbreak threshold in epidemiology.
 PLoS pathogens. 2013;9(6):e1003277.
- [43] Getz WM, Luisa Vissat L, Salter R. A Contact-Explicit Covid-19 Epidemic
 and Response Assessment Model. medRxiv. 2020;.
- [44] Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN,
 et al. Complete mapping of mutations to the SARS-CoV-2 spike receptorbinding domain that escape antibody recognition. Cell host & microbe.
 2021;29(1):44–57.
- [45] Funk S, King AA. Choices and trade-offs in inference with infectious disease
 models. Epidemics. 2020;30:100383.
- [46] Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL,
 Hudson WH, et al. Rapid generation of neutralizing antibody responses in
 COVID-19 patients. Cell Reports Medicine. 2020;1(3):100040.
- [47] Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menach ery VD, Xie X, et al. A high-throughput neutralizing antibody assay
 for COVID-19 diagnosis and vaccine evaluation. Nature communications.
 2020;11(1):1–6.
- [48] Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Im munological considerations for COVID-19 vaccine strategies. Nature Re views Immunology. 2020;20(10):615–632.
- [49] Tkachenko AV, Maslov S, Elbanna A, Wong GN, Weiner ZJ, Goldenfeld
 N. Time-dependent heterogeneity leads to transient suppression of the
 COVID-19 epidemic, not herd immunity. Proceedings of the National
 Academy of Sciences. 2021;118(17).
- [50] Anderson RM. The impact of vaccination on the epidemiology of infectious
 diseases. In: The Vaccine Book. Elsevier; 2016. p. 3–31.
- [51] Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens per sist on inanimate surfaces? A systematic review. BMC infectious diseases.
 2006;6(1):1–8.
- [52] Liu X, Huang J, Li C, Zhao Y, Wang D, Huang Z, et al. The role of
 seasonality in the spread of COVID-19 pandemic. Environmental research.
 2021;195:110874.

- ⁸⁰¹ [53] Valtonen A, Molleman F, Chapman CA, Carey JR, Ayres MP, Roininen
- H. Tropical phenology: Bi-annual rhythms and interannual variation in an Afortmanical butterflux according to 2012 A(2) = 20
- Afrotropical butterfly assemblage. Ecosphere. 2013;4(3):1–28.
- ⁸⁰⁴ [54] Lythgoe KA, Hall M, Ferretti L, de Cesare M, MacIntyre-Cockett G,
- Trebes A, et al. SARS-CoV-2 within-host diversity and transmission.
- Science. 2021;372(6539). Available from: https://science.sciencemag.
- org/content/372/6539/eabg0821.

Getz et al.

¹ APPENDICES

² A Model Construction

Here we formulate an individual-based or agent-based (ABM) SEIR epidemiological model to include host immunological waning and pathogen genetic drift
with variation across variant transmissibility and virulence and succintly refer
to it as an elaborated SIR (M-SEIR) model. [50]

$_{7}$ A.1 Assumptions, definitions, and states

The population consists of a well-mixed pool of N_0 individuals that is homogeneous except for the fact that some are uninfected (denoted S), some currently q infected (E: exposed and not yet infectious; I infectious and asymptomatic or 10 symptomatic) or have been infected and are now either dead (D) or recov-11 ered/vaccinated with some level of immunity (V) to one or more of 2^{J} pathogen 12 variants. This immunity wanes over time and its current level, augmented by 13 specified levels of variant cross-immunity, factored into an agent specific time-14 dependent variant-resistance function that impacts the shedding of mutant vari-15 ants by infectors and the within-host replication rates of mutant variants in 16 infectees. 17

At the start of the epidemic, all individuals are assumed to encounter, on 18 average, $\kappa_0 > 0$ other individuals during each time period [t, t+1], but this 19 "effective contacts" rate adaptively decreases with increasing prevalence of the 20 disease due to the implementation of non-pharmaceutical interventions (social 21 distancing, hand washing, mask wearing, and other hygienic precautions). In 22 our selection of epidemiological parameter values, a unit of time is taken to be a 23 24-hour day. Other scalings of time would then require appropriately adjusted 24 epidemiological parameter values. Refined versions of the model could include 25 age-related parameter values and contact rates, as well as contact tracing, quar-26 antining, and isolation of infected individuals; but these will not be considered 27 here. 28

Initially, at model time t = 0, all individuals are considered SARS-CoV-29 2 naïve susceptible apart from one individual who is considered to have just 30 entered the infectious stage, infected by a pathogen designated as pathogen 31 variant 0 (wildtype). Throughout the model simulation, the N_0 agents in the 32 population are partitioned into three disjoint sets: the set of SARS-CoV-2 naïve 33 individuals, $\mathbf{S}(t)$, containing $N_{\mathbf{S}}(t)$ (the susceptibles); the set of identified agents, 34 $\mathbf{A}(t)$, containing $N_{\mathbf{A}}(t)$ individuals who are either currently infected (time t) 35 with a particular variant of SARS-CoV-2, or have some level of waning immunity 36 to one or more variants of SARS-CoV-2; and the set of dead individuals $\mathbf{D}(t)$, 37 currently of size $N_{\rm D}(t)$. Only the individuals in $\mathbf{A}(t)$ are uniquely identified as 38 they become infected for the first time and make the transition from set $\mathbf{S}(t)$ to 39 set $\mathbf{A}(t)$, where they are sequentially labeled using the index $i = 1, ..., N_{\mathbf{A}}(t)$. 40 The single infected individual at time zero will be designated Agent 1 (also 41 known as patient zero and denoted by A_1). Thus at time t it follows that 42

$$N_{\rm S}(t) + N_{\rm A}(t) + N_{\rm D}(t) = N_0 \quad (\text{a constant}) \tag{A.1}$$

We note that individuals in set $\mathbf{A}(t)$ can be in a disease state E or I with respect to pathogen j, but simultaneously can be in multiple immune states if they have been infected with more than one pathogen variant in the past. We also note that the distinction between symptomatic and asymptomatic individuals in state I will not be considered here; and only need be incorporated if testing, quarantining, and treatment processes are included in the model.

The total number of pathogen variants is set by a parameter J > 0, where each pathogen is represented by a *J*-bit binary number. Thus, there are 2^{J} possible variants indexed by $j = 0, 1, 2, ..., 2^{J} - 1$ where *j* is the decimal equivalent that corresponds to a given binary string. The initial variant, j = 0 is the binary string of *J* zeros.

Sets of stochastic epidemic events (i.e., transitions from classes S to E, E to I, I to V or D) are implemented at consecutive integer points in time (one set of events for each point in time). Events will only be considered on individuals that have been infected by at least one of the pathogens at some time after t = 0(this means that initially the epidemic computation proceeds rather rapidly, but becomes more computationally intensive for each time step as time proceeds).

60 A.1.1 Pathogen set

At the start of the simulation (t = 0), the set of potential pathogens indexed by 61 $j = 0, ..., 2^J - 1$ is generated along with its associated environmental persistence 62 $(\bar{\eta}_i)$, transmission $(\bar{\beta}_i)$, within host replication (λ_i) and disease-induced mortal-63 ity rate (probability of dying from the disease p_{α_i}) parameters. These may be 64 specified or drawn from underlying distributions (e.g., the uniform distributions 65 $\beta \sim \text{Uniform}[\beta_{\min}, \beta_{\max}]$ and so on). Also, our model includes two $2^J \times 2^J$ 66 matrices of constants that are associated with pathogen mutations during vari-67 ant shedding (elements ζ_{im}) and cross-immunity (elements c_{mi}) processes and 68 thus involve but are conditioned on either the major variant that an infector 69 is harboring or on immunological state of the agents involved. These are the 70 shedding and cross-immunity matrices with elements $j, m = 0, ..., 2^{J} - 1$, Thus 71 we generate the following list of parameters associated with our 2^{J} pathogen 72 variants: 73

Pathogen list = (A.2)

$$\{ (\bar{\eta}_j, \bar{\beta}_j, \lambda_j, p_{\alpha_j}; \zeta_{jm} \text{ and } c_{mj} \text{ for } m = 0, ..., 2^J - 1 \} | j = 0, ..., 2^J - 1 \}$$

74 A.1.2 Agent states

⁷⁵ In accordance with the above set of assumptions, each agent has the following ⁷⁶ basic disease states at time t, where disease states in agent A_i are referenced by ⁷⁷ the time $\tau_j > 0$ at which the most recent infection with variant j has occurred ⁷⁸ (an individual may be re-infected after immunity to the variant has waned to ⁷⁹ relatively low levels):

1. S(t): An individual who at time t has not been infected with any variant of the pathogen up to time t. All these individuals belong to set S(t)

Submitted on August 12, 2021

- 2. $E_j(t, \tau_{ij})$: An agent A_i who was infected with variant j at time τ_{ij} , but has not yet become infectious (this is an individual in the latent stage that
- lasts for $\sigma_{\rm E}$ units of time). All these individuals belong to set ${\bf A}(t)$
- 3. $I_j(t, \tau_{ij})$: An agent A_i who is currently infectious with variant j, after being infected with variant j at time τ_{ij} (this is the infectious stage that lasts for σ_I units of time). All these individuals belong to set $\mathbf{I}(t) \subseteq \mathbf{A}(t)$
- 4. $V_j(t, \tau_{ij})$: An agent A_i who was infectious with variant j, having been infected with variant j at time τ_{ij} , but is now non-infectious with regard to this variant—that is, recovered with some immunity to variant j, as well as some cross immunity to variants closely related to j. All these individuals belong to set $\mathbf{A}(t)$

5. D(t): An individual at time t who has died after being exposed to and become infectious with some variant of the pathogen. In a refined version of the model, a record will be kept of the time of death and the variant that caused death. All these individuals belong to set D(t).

Since an agent A_i may be infected over time by more than one variant j, its complete epidemiological state is represented by a list

$$A_i(t) = \{ \text{state w.r.t. pathogen } 0, \dots, \text{state w.r.t. pathogen } 2^J - 1 \}$$
 (A.3)

If a living agent does not fall into any of the categories 2-4 with respect to pathogen j, we denote its epidemiological state at position j as \emptyset (the empty set). Consequently, if an agent A is susceptible at time t (i.e., an element of S(t)), then we write

$$\mathbf{A}_0(t) = \{\emptyset, \dots, \emptyset\} \in \mathbf{S}$$

⁹⁹ However, while such individuals are omitted from the A list (hence we did not
¹⁰⁰ subscript the agent A above), they may be recognized as "virtual members"
¹⁰¹ with this implicit state. Some other examples are:

• If $A_i(t)$ is infected, but not yet infectious, with pathogen variant j at time t but has not been infected with any other pathogen in its past history, then

$$A_i(t) = \{\emptyset, \cdots, \emptyset, E_j(t, \tau_j), \emptyset, \cdots, \emptyset\}$$

• On the other hand if A_i recovered from an infection with pathogen 0 at time τ_0 , and is now infectious with pathogen j at time t, having become infected with this pathogen at time τ_i then we write

$$\mathbf{A}_{i}(t) = \{ \mathbf{V}_{0}(t, \tau_{0}), \emptyset, \cdots, \emptyset, \mathbf{I}_{i}(t, \tau_{i}), \emptyset, \cdots, \emptyset \}$$

¹⁰² As we shall see, an agent history may contain at most one instance of either E_j ¹⁰³ or I_j , while possibly containing multiple instances of V_j .

Submitted on August 12, 2021

104 A.1.3 Agent and index sets

At the start of each time period, we update the set of identified agents \mathbf{A} by adding susceptibles that became infected with pathogens during the previous time period and removing agents that died during the previous time period. Thus if $\mathbb{I}_{\mathbf{A}}$ is the index set for non-empty elements of \mathbf{A} , with new indices added for newly infected susceptibles and indices removed for individuals that died, then by definition:

$$\mathbf{A}(t+1) = \{\mathbf{A}_i(t+1) | i \in \mathbb{I}_{\mathbf{A}}(t+1)\}$$
(A.4)

where the number of indices in the updated set $\mathbb{I}_{A}(t+1)$ is $N_{A}(t+1)$ and the updated number of dead is $N_{D}(t+1)$ at time t+1.

For mathematical convenience all susceptibles S will also be referred to as A₀:, i.e., there are $N_{\rm S}(t)$ individuals referenced by A₀ at time t. It will be useful to partition the set $\mathbf{A}(t)$ itself into three subsets at time t by identifying the sets $\mathbf{E}(t)$ and $\mathbf{I}(t)$ which respectively contain all agents that are currently in a state $\mathbf{E}_{j}(t)$ or a state $\mathbf{I}_{j}(t)$ at time t for some $j = 0, ..., 2^{J} - 1$. We note the intersection of these two sets is empty—i.e., $\mathbf{E}(t) \cap \mathbf{I}(t) = \emptyset$ —as will become apparent below from the transmission process rules set up below. We will use the notation

$$\mathbf{A}_{\mathrm{S}}(t) = \mathbf{A}(t) \setminus \left(\mathbf{E}(t) \cup \mathbf{I}(t) \right)$$
(A.5)

to denote the set of agents in $\mathbf{A}(t)$ but not in $\mathbf{E}(t)$ or $\mathbf{I}(t)$.

We also identify the set of infectious agents with infectious variant j. If A^j denotes an agent whose epidemiological state contains an entry $I_i(t, .)$, then

$$\mathbf{I}_{j}(t) = \{\mathbf{A}_{i_{1}}^{j}(t), \mathbf{A}_{i_{2}}^{j}(t), \dots, \mathbf{A}_{i_{N_{1}}}^{j}(t)\},\$$

where the number of such agents is denoted by $N_{I_i}(t)$, and its index set by

$$\mathbb{I}_{\mathbf{I}_{j}}(t) = \{i_{1_{j}}, \dots, i_{N_{\mathbf{I}_{i}}}(t)\}.$$

121 A.2 Epidemiological processes

122 A.2.1 Immunity

In compartmental SIRS and SEIRS models, a concept of waning immunity and 123 its impact on epidemics is associated with the rates at which individuals in class 124 R revert back to class S. In agent-based SIRS and SEIRS models, we have the 125 opportunity to consider the immunological history of individuals and, hence, 126 can take a more refined approach to the complex process of how pathogens in 127 an infector A_i are passed on the an infectee A_h . Here we model this as a prob-128 ability generated from a concatenation of rates that include pathogen shedding 129 by A_i , the survival of pathogens in the environment, whether contained in feces, 130 urine, sweat, mucosal secretions or water droplets excreted by an infector, and 131 a process whereby pathogens gain access to a host (entering through wounds, 132 mucosal membranes or other membranes in the pulmonary or alimentary sys-133 tems). We then characterize pathogen within-host variant replication rates in 134 terms of pathogen mutational and reproductive processes. The final outcome 135

Submitted on August 12, 2021

Getz et al.

in our model is either host recovery with some immunity or host death. We
also consider the induction of host immunity through vaccination and make the
assumption that waning immunity is the same, whether it stems from natural
infection or vaccination. Of course, these may be modelled in different ways
should data become available to make this distinction an important modeling
consideration.

142

Waning immunity. Recall that we use A_0 to denote an anonymous (generic) member of **S** and that A_i for i > 0 refers to a specific individual with an associated state list/vector. If some specific A_i is in immune state V_j having been infected with this variant at time τ_{ij} , we assume that the level of relative susceptibility of agent A_i to reinfection by variant j is given by (noting that the existence of the value τ_{ij} implies that infection of individual i by variant j at time τ_{ij} ensures that the V_j is no longer "null")

$$\omega_{ij}(t,\tau_{ij}) = \begin{cases} 0 & \text{if } \mathbf{V}_j \text{ is null} \\ \frac{1}{1 + \left((t - \tau_{ij} - \sigma_{\mathbf{I}} - \sigma_{\mathbf{E}})/t_j^{\text{half}} \right)^{\sigma}} & \text{if } t \ge \tau_{ij} + \sigma_{\mathbf{I}} + \sigma_{\mathbf{E}} \\ 1 & \text{if } t < \tau_{ij} + \sigma_{\mathbf{I}} + \sigma_{\mathbf{E}} \end{cases}$$
(A.6)

We note the following: 1.) the first case implies that τ_{ij} has yet to be defined; 150 2.) the second case is equivalent to the statement that $\tau_{ij} \geq 0$ now exists for 151 variant j, since this occurs at time $t = \tau_{ij}$ (through the invocation of state 152 $E_j(t,\tau_{ij})$; 3.) $\omega_{ij}(t,\tau)$ ranges from 1 (i.e. full "on") at $t = \tau + \sigma_I + \sigma_E$ and 153 decays to 0 as $t > \tau + \sigma_{\rm I} + \sigma_{\rm E} \to \infty$; 4.) agent *i* cannot be reinfected with 154 its current major variant or with any other variant while it is currently itself in 155 any state E_i or I_i for any $j = 0, ..., 2^J - 1$; 5.) the larger the value of σ the 156 steeper or more abrupt the switch is from full immunity (equal to 1) at time τ 157 through 1/2 at time t_i^{half} to approach 0 as $t \to \infty$ (we set $\sigma = 4$ as providing 158 an intermediate level of abruptness). 159

160

¹⁶¹ <u>Vaccination</u>. A vaccine may be designed to give immunity to one or more ¹⁶² particular identified variant j. Vaccination strategies include vaccinating at a ¹⁶³ fixed rate v(t) (percent of individuals vaccinated at each time period) over a ¹⁶⁴ fixed period that begins at t_v^{on} and ends at t_v^{off} and can focus on drawing only ¹⁶⁵ on: i) individuals in the set \mathbf{S} , ii) any non-infectious individual in \mathbf{S} or \mathbf{A} , or iii) ¹⁶⁶ any non-infectious, not previously vaccinated individual in \mathbf{S} or \mathbf{A} . The vaccine ¹⁶⁷ itself can be designed as follows:

- Dominant variant vaccination at time τ_{vac} . An individual S or A_i vaccinated with the dominant variant, say j, at time $\tau_{\text{vac}} \in [t_v^{\text{on}}, t_v^{\text{off}}]$ serves to add the disease state $V_j(t, \tau_{\text{vac}})$ to that individual's list. If the individual is already in state $V_j(t, \tau')$ at time $t > \tau_{\text{vac}}$, then its status is updated so that at time $t > \tau_{\text{vac}}$ it is now $V_j(t, \tau_{\text{vac}})$ rather than $V_j(t, \tau')$
- Multivariant vaccination at time t_{vac} . An individual S or A vaccinated with a multi variant concoction at time $\tau \in [t_v^{\text{on}}, t_v^{\text{off}}]$, say with variant j_1, \ldots, j_v , will have their disease status updated with regard to all these variants, as in the dominant variant case.

Submitted on August 12, 2021

177 A.2.2 Infectious contacts

Infectious individuals are assumed to make $\hat{\kappa}$ effective contacts each time period; 178 where effective contacts are those that are sufficiently close and of a sufficiently 179 long duration to constitute a "risk of transmission." This rate is either a con-180 stant κ_0 , or in stochastic implementations drawn from a Poisson distribution 181 with mean κ_0 , or in adaptive formulations (e.g., under social distancing be-182 haviour) is a function of the severity of the ongoing outbreak. We also assume at 183 time t that under a random contact process, proportion $\frac{\hat{\kappa}(t)N_{\rm S}(t)}{N_0 - N_{\rm D}(t)}$ and $\frac{\hat{\kappa}(t)N_{\rm A}(t)}{N_0 - N_{\rm D}(t)}$ 184 of these contacts will respectively be with susceptible and with uniquely identified agents, although only $\frac{\hat{\kappa}(t)(N_{\rm A}(t) - N_{\rm E}(t) - N_{\rm I}(t))}{N_0 - N_{\rm D}(t)}$ of those will be susceptible to 185 186 infection with a new variant or reinfection with the same variant. 187

In the adaptive case, we assume $\kappa(t)$ decreases from κ_0 as the proportion of infectious individuals, $N_{\rm I}(t)/(N_0 - N_{\rm D}(t))$, increases such that $\kappa(t) = \kappa_0/2$ when $N_{\rm I}(t)/(N_0 - N_{\rm D}(t)) = p_{\rm I}^{\rm half}$. For convenience of implementation, however, we define the following "switching" (as apposed to hyperbolic) function

$$\kappa(t) = \begin{cases} \frac{\kappa_0}{1 + \left(\frac{N_{\rm I}(t)}{N_0 - N_{\rm D}(t)} / p_{\rm I}^{\rm half}\right)^2} & \text{when } p_{\rm I}^{\rm half} > 0\\ \kappa_0 & \text{when } p_{\rm I}^{\rm half} = 0 \end{cases}$$
(A.7)

even though, from a continuity point of view, the top part of this expression implies that $\kappa(t) \to 0$ at $p_{\rm f}^{\rm half} \to \infty$.

¹⁹⁴ A.2.3 Probability of infection

209

In deriving a probability $\pi_{ih,j\ell}^{\inf}$ of an agent A_h being infected with variant ℓ 195 by an agent A_i who is infectious with major variant j, we concatenate (i.e., 196 multiply together) several process, each of which involves nominal constants. 197 Thus, in all but one of these processes, the scaling of these constants can be 198 normalized and given a relative set of values across variants though one set of 199 constants though relative, will ultimately all be scaled by fitting the model to 200 real data. In our treatment below, constants associated with shedding and per-201 sistence will be scaled while those associated with within-host replication will be 202 kept unscaled to be ultimately fitted to data. In particular, the parameters $\hat{\beta}_i$ 203 associated with pathogen transmission (i.e., from contact to the start of within 204 host replication—see Fig. 1) will be scaled by fitting to epidemiological data, 205 while the relative values for the different variants regarding pathogen shedding 206 and environmental persistence can be fitted to experimental data collected to 207 set values of these processes when considered on their own. 208

Pathogen shedding. We assume that shedding is affected by the immune state of the infector A_i and thus posit the shedding rates below for this individual when its major infectious variant is j. In general, we have a matrix of shedding rates $\bar{\zeta}_{j\ell}$ before accounting for immunity and cross immunity that is specific to agent A_i . Immunity and cross-immunity act to reduce shedding rates through functions $\phi_{ij}(t) \in [0, 1]$ that are computed in terms of A_i 's waning functions ω_{im} with respect to variant m and a matrix of cross-immunity values c_{jm} that have been normalized so that $c_{jj} = 1$ for $j = 0, ..., 2^J - 1$ and $c_{jm} \in [0, 1]$ for

Submitted on August 12, 2021

239

Getz et al.

 $j, m = 0, ..., 2^J - 1$. Specifically, we define agent-specific *immunity modifying* functions

$$\phi_{ij}(t) = \prod_{m=0}^{2^{J}-1} \left(1 - c_{mj}\omega_{im}(t)\right)$$
(A.8)

²²⁰ and assume that the shedding rates can be expressed as

$$\zeta_{ij\ell}(t) = \overline{\zeta}_{j\ell}\phi_{i\ell} \qquad \ell = 0, \dots, 2^J - 1 \tag{A.9}$$

Environmental persistence. The persistence of pathogens in the environment 221 are known to be impacted by humidity, temperature, airflow, and the surface 222 properties of fomites [51]. This, and other factors relating the effects of weather 223 on contact rates and efficacy, may result in overall pathogen transmission having 224 a seasonal component to it [52]. In particular, viral persistence indoors may 225 be much greater than outdoors, with a greater proportion of indoor contacts 226 taking place during cold or wet weather. Thus the most appropriate place 227 to introduce seasonal effects into epidemic processes is through contact rates 228 and environmental persistence cycling over time with a period of one year (or 229 even half-a-year if two comparatively spaced rainy seasons occur, as in some in 230 tropical locations [53]) and an amplitude obtained by fitting parameters to data. 231 Thus, in our model, we introduce constants $\bar{\eta}_{\ell}$, $\delta_{\text{season}} \in (0, 1)$, k (appropriately 232 scaled, depending on the units of time) and θ and assume that 233

$$\eta_{\ell}(t) = \bar{\eta}_{\ell} \left(1 + \delta_{\text{season}} \sin\left(\frac{2\pi t}{k} + \theta\right) \right) \qquad \ell = 0, ..., 2^{J} - 1 \tag{A.10}$$

The case $\delta_{\text{season}} = 0$ corresponds to constant values $\eta_{\ell}(t) = \bar{\eta}_{\ell}$ for all t, while if $\delta_{\text{season}} = 1$ we get the largest possible fluctuation between 0 and $2\bar{\eta}_{\ell}$. The constant k relates to the time units so we get one cycle per year, and θ shifts the cycle to set the points in time at which the maximum and minimum values of $\eta_{\ell}(t)$ occur.

²⁴⁰ <u>Variant transmission</u>. In the context of a standardized dose (which will be ²⁴¹ modified by multiplying the variant *effective contact* and transmission by both ²⁴² pathogen shedding and environmental persistence functions), the differential ²⁴³ rates of variant transmission, which we denote by $\beta_{h\ell}$, will depend on a constant ²⁴⁴ variant transmission rate parameter $\bar{\beta}_{\ell}$ modified by a function that represents ²⁴⁵ the immune state of the infectee at time t: viz., recalling SOF Eq. A.8

$$\beta_{h\ell}(t) = \bar{\beta}_{\ell} \phi_{h\ell}(t), \quad \ell = 0, ..., 2^J - 1$$
 (A.11)

Probability of infection. Using a competing rates formulation [37] to compute the probability of infection as a concatenation of the process of infector shedding (ζ), environmental persistence (η) and transmission rates (β), we obtain

$$\pi_{ih,j\ell}^{\inf}(t) = \frac{\zeta_{ij\ell}(t)\eta_{\ell}(t)\beta_{h\ell}(t)}{\sum_{m=0}^{2^{J}-1}\zeta_{ijm}(t)\eta_{m}(t)\beta_{hm}(t)} \left(1 - e^{-\zeta_{ij\ell}(t)\eta_{\ell}(t)\beta_{h\ell}(t)}\right), \quad \ell = 0, ..., 2^{J} - 1$$
(A 12)

Submitted on August 12, 2021

A.2.4 Within-host processes

If after receiving an initial infectious dose of pathogen, an individual is infected primarily with variant ℓ , then we expect this variant to dominate unless intrinsic mutational processes are high (which is not the case for COVID-19) or the individual has some immunity to this dominant variant. In the latter case the situation is ripe for an "idealized escape mutation," that is one that evades the immune system completely, to arise.

If we nominally set the relative rate at which an individual invaded by variant 256 ℓ has an infection dominated by variant ℓ (i.e., ℓ in the terminology of [54] is 257 the major variant of the infection) to be $(1 - \mu)$, then the probability that one 258 of the other variants is $\ell' \neq \ell$ is μ (in the case of COVID we assume that $\mu > 0$ 259 is very close to 0—e.g. of order 10^{-3} to 10^{-6} —while for viruses lacking error 260 correcting machinery it can be considerably larger and of the order 10^{-1}). We 261 can partition the latter probability according to a set of comparative variant 262 within-host replication rates $\lambda_{\ell'}$, each moderated by its immune state function 263 $\phi_{h\ell'}$ and a normalizing factor $\frac{1}{\sum_{\forall m \neq \ell} \lambda_m \phi_{hm}}$ to obtain 264

$$\pi_{h\ell\ell'}^{\text{inv}}(t) = \begin{cases} 1-\mu & \text{for } \ell' = \ell \\ \mu\left(\frac{\lambda_{\ell'}\phi_{h\ell'}}{\sum_{\forall m \neq l}\lambda_m\phi_{hm}}\right) & \text{for } \ell' \neq \ell \end{cases}$$
(A.13)

We stress that the parameter μ pertains to generating the probability for the transmission of mutants and is not an actual mutation rate for the virus (e.g., the host may have some mechanisms for removing most of the mutants before transmission of remaining variants occurs).

²⁶⁹ A.2.5 Pathogen progression equations

Probability that infector A_i with major variant j will result in infectee A_h express ℓ' as its major variant is

$$\pi_{ih,j\ell'}(t) = \sum_{\ell=0}^{2^J - 1} \pi_{ih,j\ell}^{\inf}(t) \pi_{h\ell\ell'}^{\operatorname{inv}}(t), \quad \ell = 0, ..., 2^J - 1$$
(A.14)

272 A.2.6 Single-variant case

In the single-variant case (J = 0), the waning immunity equation SOF Eq. A.6 reduces to (dropping the redundant index j = 0, and noting that the existence of a value τ_i implies A_i has been infected at time τ_i in the past)

$$\omega_{i}(t) = \begin{cases} 0 & \text{if } A_{i} \text{ has never been infected} \\ \frac{1}{1 + \left((t - \tau_{i} - \sigma_{I} - \sigma_{E})/t^{\text{half}} \right)^{\sigma}} & \text{if } t \geq \tau_{i} + \sigma_{I} + \sigma_{E} \\ 1 & \text{if } t < \tau_{i} + \sigma_{I} + \sigma_{E} \end{cases}$$
(A.15)

(recall we set $\sigma = 4$) and the modifying immunity functions ϕ_{ij} (SOF Eq. A.8) collapse to 1, which implies that the pathogen shedding functions $\bar{\zeta}_{i\ell}$ (SOF

Submitted on August 12, 2021

Getz et al.

Eq. A.9) collapse to 1. Without loss of generality, we can also assume a singlevariant value of $\eta = 1$ in SOF Eq. A.10, which implies that the probability of infection (SOF Eq. A.12) reduces to

$$\pi_{ih}^{\inf}(t) = 1 - e^{-\bar{\beta}(1 - \omega_h(t))} \tag{A.16}$$

Further, since in the single-variant case there are no mutations to consider, it follows from SOF Eq. A.13 that $\pi_{h\ell\ell'}^{\text{inv}}(t) = 1$ for all h and we finally have that $\pi_{ih}(t) = \pi_{ih}^{\inf}(t) = 1 - e^{-\bar{\beta}(1-\omega_h(t))}$ (SOF Eq. A.14) for all h.

²⁸⁴ A.3 Simulation algorithm

286

287

288

290

291

292

293

294

295

296

297

298

290

300

301

302

303

304

305

307

308

309

311

312

1. Parameters selected at the start of a simulation

- (a) N₀: Number of individuals in the population. Assumed to be fixed over time (i.e., the population is closed), but partitioned into sets S, A and D with respectively N_S(t), N_A(t) and N_D(t) individuals in each set and satisfying SOF Eq. A.1.
 (b) I: The lag of the number of possible union indexed by i.
 - (b) J: The \log_2 of the number of possible variants indexed by $j = 0, \cdots, 2^J 1$
 - (c) β_j : variant dependent transmission parameters (the process between contact and the start of variant replication and nominally equivalent to transmission in SEIR models—see Fig. 1) for pathogen variant j
 - (d) t_j^{half} : The time it takes for immunity to variant j to have waned by half.
 - (e) σ_{E_j} : The time it takes from initial infection for an infected individual to become more likely to become infectious than remain infected without being infectious.
 - (f) σ_{I_j} : The additional time it takes beyond σ_{E_j} for an infectious individual to more likely transition beyond being infectious than remain infectious.
 - (g) p_{α_j} : The proportion of individuals leaving the infectious category that die, which implies that $1 p_{\alpha_j}$ is the proportion that become immune.

306 2. Initialization

- (a) Set up pathogen list (see Eq. A.2)
- (b) Initialize the simulation by setting t = 0 and creating the agent list $\mathbf{A}(0)$ one infectious and $N_0 1$ susceptible agents.

310 3. Time *t*: vaccination loop.

- (a) Carry out the vaccination process before going into the rest of the loops with the updated S and A sets after the vaccinations.
- 4. **Time** *t*: **contact loop.** Set up contacts for the current round of encounters at time *t* (i.e., the inner agent-driven contact loop within the outer time-driven loop) and tag for outer loop update of disease status, as follows:

Submitted on August 12, 2021

317

318

319

321

322

323 324

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

Getz et al.

- (a) Numbers in various sets and associated index sets. Identify the number of individuals $N_{\rm S}(t)$, $N_{\rm A}(t)$ and $N_{\rm D}(t)$ in sets **S**, **A** and **D** at time t respectively, as well as the number of exposed (but not yet infectious) agents $N_{\rm E}(t)$, infectious agents $N_{\rm I}(t)$ and identified non-infected agents $N_{\rm A_S}(t) = N_{\rm A}(t) N_{\rm I}(t) N_{\rm E}(t)$. Break down the infectious agents tally into the number of agents $N_{\rm I_j}$ infectious with variant $j = 0, 1, ..., 2^J 1$. We will also need the index sets $\mathbb{I}_{\rm A_S}$ and $\mathbb{I}_{\rm I_j}(t), j = 0, ..., 2^J 1$ at time t.
 - (b) Infectious contacts with each group. The rate at which any individual contacts other individuals per unit time is given by the contact rate parameter $\kappa > 0$. Assuming random contact events over one unit of time, the actual number of individuals that agent A_i contacts at time t is then given by

$$\hat{\kappa}_i(t) \sim \text{POISSON}[\text{mean} = \kappa(t)]$$

³²⁵ Of these, proportions

$$\pi_{i\rm S} = \frac{N_{\rm S}(t)}{N_0 - N_{\rm D}(t)} \tag{A.17}$$

and

$$\pi_{iA} = \frac{N_A(t) - N_I(t) - N_E(t)}{N_0 - N_D(t)}$$
(A.18)

are expected to come from susceptibles in the sets $\mathbf{S}(t)$ and $\mathbf{A}_{\mathbf{S}}(t)$ (see Eq. A.5) respectively. Thus the actual number of contacts in set $\mathbf{S}(t)$, $\mathbf{A}_{\mathbf{S}}(t)$, and $\mathbf{E}(t) \cup \mathbf{I}(t)$ are

$$\left(\hat{N}_{i}^{\mathrm{S}}(t), \hat{N}_{i}^{\mathrm{A}_{\mathrm{S}}}(t), \hat{N}_{i}^{\mathrm{E}}(t) + \hat{N}_{i}^{\mathrm{I}}(t)\right) =$$
(A.19)

Multipopial [$\hat{k}: \pi \in \pi \cup 1$ are $\pi \cup 1$

 $\texttt{Multinomial}\left[\hat{\kappa}_{i}; \pi_{i\mathrm{S}}, \pi_{i\mathrm{A}}, 1 - \pi_{i\mathrm{S}} - \pi_{i\mathrm{A}}\right]$

We note that only $\hat{N}_i^{\rm S}(t)$ and $\hat{N}_i^{\rm A_{\rm S}}(t)$ are of interest because individual in states E and I cannot be reinfected. Also, we make the assumption below that the first infection that an individual in set **A** contracts in this contact loop, is the one that counts (i.e., there will be no simultaneously infections with multiple variants). Finally, since contacting individuals is tantamount to sampling with replacement, the number of unique contacts (i.e., all multiple contacts are counted as a single contact) that agent A_i has with individuals in the set **S** is $\hat{N}_i^{\rm S}(t)$ reduced by excluding multiple contacts (which under a random contact model is a negative exponential correction) to obtain

$$N_i^{\rm S*}(t) = \min\left\{\hat{N}_i^{\rm S}(t), \text{Binomial}\left[\hat{\kappa}_i(t), e^{-\hat{\kappa}_i(t)/\hat{N}_i^{\rm S}(t)}\right]\right\}$$
(A.20)

Thus if $\hat{\kappa}_i(t) << \hat{N}_i^{\mathrm{S}}(t)$, $N_i^{\mathrm{S}*}(t)$ is expected to be very close to the upper value $\hat{\kappa}_i(t)$. On the other hand, if $\hat{\kappa}_i(t) \approx \hat{N}_i^{\mathrm{S}}(t)$, then $N_i^{\mathrm{S}*}(t)$ is expected to be around $\hat{\kappa}_i(t)/e \approx 0.37 \hat{\kappa}_i(t)$. Additionally, after dealing with each agent *i* reduce in the size of $N_{\mathrm{S}}(t)$ to take account of those agents that had been infected by agent A_i and had now entered the ranks of the set **A**.

Submitted on August 12, 2021

(c) Identify all infectious agents and their pathogens variants. Among all agents in the set $\mathbf{A}(t)$ (Eq. A.4), identify those that have an infectious variant \mathbf{I}_j for some $j = 0, \dots, 2^J - 1$. Thus, if the number of infectious agents with infectious variant j is $N_{\mathbf{I}_j(t)}$ then consider the set

$$\mathbf{I}_{j}(t) = \{\mathbf{A}_{i_{1}}^{j}(t), \mathbf{A}_{i_{2}}^{j}(t), \dots, \mathbf{A}_{N_{\mathbf{I}_{j}}}^{j}(t)\}$$

with index set

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

363

364

365

366

367

368

369

370

371

372

373

$$\mathbb{I}_{\mathbf{I}_{j}}(t) = \{i_{1_{j}}, \cdots, i_{N_{\mathbf{I}_{j}}(t)}\}$$

Initially, most of these sets will be empty, but will fill in over time.

(d) Susceptible contacts. The probability that an agent A_i with a variant j major infection infects a susceptible (nominally denoted by individuals of type A_0) who then becomes infectious with dominant variant ℓ' is given by the probability $\pi_{i0,j\ell'}$ computed in Eq. A.14, which itself relies on expressions Eq. A.7-A.13. The actual number of individuals in the set **S** will make effective contact with one more infectious individuals is $N_i^{S*}(t)$ obtained using Eq. A.20. Thus, from a multinomial drawing, we can now generate the number of newly exposed individuals, $N_{0\ell'}^{E+}(t+1)$ (the "+" is used to denote these are newly added and the "0" that they are coming from the set **S**), with major variant ℓ' at time t + 1, have been infected by agent A_i with major pathogen variant j on the time interval [t, t + 1):

These individuals will be used to update list of currently infected individuals in the sets $\mathbf{A}_{\mathrm{E}_j}$, $j = 0, ..., 2^J - 1$ at time t+1, which is computed in the outer loop computation, as presented below. We also note that the probabilities in the above multinomial add to less than 1, so that at the end of the drawing a proportion of the individuals $N_i^{\mathrm{S*}}(t)$ remain uninfected.

(e) Agent contacts. The number of agents $\hat{N}_i^{A_S}(t) \in \mathbb{I}_{A \setminus (E \cup I)}$ that come into contact with agent A_i over the interval (t, t + 1) is given by Eq. A.19. This number is drawn from the set $\mathbb{I}_{A \setminus (E \cup I)}$ with replacement and the following multinomial computation is used to determine how to update agent A_h at time t + 1 when coming into contact with agent A_i on the interval (t, t + 1) using the probabilities of transmission given in Eq. A.14. Specifically, agent A_h will become infected with major variant ℓ' at time t + 1 is determined by the multinomial drawing

$$A_h \in \mathbf{A}_{\mathrm{E}_j} \text{ for some } j \sim \mathtt{Multinomial} \begin{bmatrix} 1; \pi_{ih,j0}(t), \cdots, \pi_{ih,j\,2^J-1}(t) \end{bmatrix}$$
(A.22)

We note here that since the agents A_h , $h \in \mathbb{I}_{A \setminus (E \cup I)}$ are drawn with replacement as the computation proceeds and the agents A_i , $i \in \mathbb{I}$ are cycled through, if a previously drawn A_h is drawn again, but has already

39

Getz et al.

Submitted on August 12, 2021 Getz et al.

been infected in the current round then we ignore the latest event, but keep the previous infection event intact. To obviate bias in this procedure, we need cycle through the agents $A_i, i \in \mathbb{I}$ at random rather than in numerical

order.

382

383

384

385

386

387

388

389

395

396

397

398

5. Time *t*: disease progression loop.

(a) Individuals in \mathbf{A}_{E} at time t. An individual $A_i \in \mathbf{A}_{\mathrm{E}}$ at time t and in state $\mathrm{E}_j(t,\tau_i), j = 0, ..., 2^J - 1$, becomes either an individual in state $\mathrm{E}_i(t+1,\tau_i)$ with probability

$$\pi_{\mathbf{E}_j}(t) = \frac{1}{1 + \left(\frac{t - \tau_i}{\sigma_{\mathbf{E}_j}}\right)^4} \tag{A.23}$$

or transfers to state $I_j(t+1, \tau_i)$ with probability $(1 - \pi_{E_j}(t))$ thereby entering class A_I at time t + 1.

(b) Individuals in \mathbf{A}_{I} at time t. An individual $\mathbf{A}_{i} \in \mathbf{A}_{\mathrm{I}}$ at time t and in state $\mathbf{I}_{j}(t,\tau_{i}), j = 0, ..., 2^{J} - 1$, becomes either an individual in state $\mathbf{I}_{i}(t+1,\tau_{i})$ with probability

$$\pi_{\mathbf{I}_j}(t) = \frac{1}{1 + \left(\frac{t - \tau_i}{\sigma_{\mathbf{E}_j} + \sigma_{\mathbf{I}_j}}\right)^4} \tag{A.24}$$

or leaves the set $I_j(t + 1, \tau_i)$ with probability $(1 - \pi_{I_j}(t))$. In this latter case, the individual either dies with probability p_{α_j} or enters the state $V_j(t + 1, \tau_i)$ at time t + 1 with probability $1 - p_{\alpha_j}$ The total number of individuals dying over the interval [t, t + 1) is noted as having a value $\Delta N_D(t)$.

6. Time t + 1: outer loop update. The outer loop records all the events that took place in the contact and disease progression loops and updates the agents state at the next time step. It also updates all other states as follows.

(a) Individuals in \mathbf{A}_{S} at time t. For the $N_{\mathrm{S}}(t)$ individuals in \mathbf{A}_{S} at time t, we have $N_{0i}^{\mathrm{E}+}(t)$ enter set $\mathbf{A}_{\mathrm{E}_{i}}(t+1)$ and we update

$$N_{\rm S}(t+1) = N_{\rm S}(t) - \sum_{j=0}^{2^J - 1} N_{0j}^{\rm E+}(t)$$

399 400

401

402

403

404

405

406

407

where Eq. A.20 ensures that $N_{\rm S}(t+1) \ge 0$

- (b) Individuals in \mathbf{A}_{S} that are infected again over [t, t+1). These individuals can become reinfected as calculated in the contact loop. Those that become reinfected with variant $j, j = 0, ..., 2^{J} - 1$ enter state $\mathbf{E}_{j}(t+1, t+1)$ at time t+1.
- (c) Updating the immunity of individuals in \mathbf{A}_{S} . Every individual within \mathbf{A}_{S} at time t must have its immunity status updated so that for $j = 0, ..., 2^{J} 1$, if \mathbf{A}_{i} is in state $\mathbf{V}_{j}(t, \tau_{ij})$ at time t then it transfers to state $\mathbf{V}_{j}(t+1, \tau_{ij})$ at time t+1, even if reinfected, as in b.) above.

Submitted on August 12, 2021

408

409

410

411

412

(d) Transfer from **S** to **A**. The $\hat{N}_{0j}^{E}(t)$ computed in Eq. A.21 become newly listed members of the set **A** by entering state $\mathbf{E}_{j}(t+1,t+1)$, $j = 0, ..., 2^{J} - 1$. This involves updating the equations for $N_{\rm S}(t)$ and $N_{\rm A}(t)$, including taking account of the number of individuals $\Delta N_{\rm D}(t)$ that died from the disease in the immediate time period, i.e.:

$$N_{\rm S}(t+1) = N_{\rm S}(t) - \sum_{j=0}^{2^J - 1} \hat{N}_{0j}^{\rm E}(t)$$

$$N_{\rm A}(t+1) = N_{\rm A}(t) + \sum_{j=0}^{2^J - 1} \hat{N}_{0j}^{\rm E}(t) - \Delta N_{\rm D}(t) \qquad (A.25)$$

$$N_{\rm D}(t+1) = N_{\rm D}(t) + \Delta N_{\rm D}(t)$$

(e) Along with input parameter values $t_{\text{vac_on}} \geq 0$, $t_{\text{vac_off}}$ and $p_v \in [0, 0.1]$, we also need to specify the valency of the vaccination by selecting 1 to 4 numbers that take on values $0, ..., 2^J - 1$ (if more valencies are needed than 4, then the platform needs to be modified accordingly). We also need specify whether N_{select} will just be individuals in the set $\mathbf{S}(t)$ ($N_{\text{select}} = N_{\text{S}}$) or will be any individual other than those in the set $\mathbf{A}_{\text{I}}(t)$ ($N_{\text{select}} = N_{\text{S}} + N_{\text{A}} - N_{\text{I}}$).

In Algorithm 1 we summarise the steps of the simulation algorithm, as described in this section. On the right we report the name and numbering of the subsections while in the for loops we list the various steps respecting the item letters. Note that technical steps not explicitly described in the text (e.g. store updates, store set progression) do not present letters or numbers. The time set is defined with T while to describe temporal progression of set \mathbf{S}, \mathbf{A} and \mathbf{D} we use the symbols $\mathcal{S}, \mathcal{A}, \mathcal{D}$ respectively.

427 A.4 Estimation of R_0 .

In a finite population, a pathogen can emerge from a single infection with probability $p_{\text{outbreak}} = 1 - 1/R_0$ if $R_0 > 1$, otherwise an outbreak will not occur [42]. Thus we can estimate R_0 if we have an estimate of p_{outbreak} and the use the following relationship to compute R_0

$$R_0 = \frac{1}{1 - p_{\text{outbreak}}} \tag{A.26}$$

For the set of parameters listed in Table 2, from 100 runs (runtime seed goes from 0 to 99 in 100 separate simulations) of the single strain case, we estimated $p_{\text{outbreak}} \approx 0.68$ from the the proportion of simulations that had positive prevalence after 100 days. From Eq. A.26 this implies that $R_0 \approx 3.1$, with a 95% confidence interval of $R_0 \in [2.4, 4.3]$ (this of course can be narrowed down with additional simulations, but a more precise estimate is not particularly relevant to our illustrative results).

Submitted on August 12, 2021

Getz et al.

Algorithm 1: Summary of simulation algorithm input N_0 , J, $\bar{\beta}_j$, t_j^{half} , σ_{E_j} , σ_{I_j} , p_{α_j} , $j = 0, ..., 2^J - 1$ // 1)parameters $\{(\bar{\eta}_j, \bar{\beta}_j, \lambda_j, p_{\alpha_j}; \zeta_{jm} \text{ and } c_{mj} \text{ for } m = 0, ..., 2^J - 1)$ // 2a) pathogen $j = 0, ..., 2^J - 1$ // list $t = 0, N_{\rm I}(0) = 1, N_{\rm S}(0) = N_0 - 1$ // 2b) initialization for t in T do if $N_{\rm I} > 0$ then for agent in $\mathbf{S} \cup (\mathbf{A} \setminus \mathbf{I})$ do // 3) vaccination loop 3a) Vaccination process Update $N_{\rm S}$ and $N_{\rm A}$ for agent in I do // 4) contact loop 4a) Numbers in various sets and associated index sets 4b) Infectious contacts with each group 4c) Identify all infectious agents and their pathogens variants 4d) Susceptible contacts 4e) Agent contacts Store updates for agent in E do // 5a) disease progression loop 5a) Individuals in \mathbf{A}_{E} at time t Store updates for agent in I do // 5b) disease progression loop 5b) Individuals in \mathbf{A}_{I} at time t Store updates Updates from loops 4), 5a) and 5b) 6a) Individuals in A_S at time t // 6) updates in outer loop 6b) Individuals in \mathbf{A}_{S} that are infected again over [t, t+1)6c) Updating the immunity of individuals in $A_{\rm S}$ 6d) Transfer from **S** to **A** 6e) Specify the valency of the vaccination $\mathcal{S}[t] \leftarrow \mathbf{S}(t)$ // store set progression $\mathcal{A}[t] \leftarrow \mathbf{A}(t)$ $\mathcal{D}[t] \leftarrow \mathbf{D}(t)$ return $\mathcal{S}, \mathcal{A}, \mathcal{D}$

Getz et al.

439 **B RAMP** Details

440 B.1 General description

An open and expressive design of the model platform aids in and encourages ex-441 ploration and experimentation. The RAMP design augments a desktop simula-442 tion platform with several novel features that increase flexibility and expressive-443 ness, and promote experimentation and interoperability with other platforms. 444 These include an API ("application programming interface") fully supporting 445 remote operation and direct retrieval of data for external processing on other 446 platforms, such as Python, Javascript or the R statistical platform. The API 447 can also be accessed by an onboard scripting interface that uses the Nashorn 448 Javascript engine. 449

Additionally, using a novel design, elements of the internal algorithm are
exposed for possible reprogramming in a secure fashion that will not damage
the overall system. These runtime alternative modules (RAMs) may also be
controlled from the API to facilitate selective algorithm redefinition during the
run of the simulation.

Use of the RAMP features require some experience with scripting and/or
Java coding, however the resulting modifications to the algorithm can be of great
significance. The RAM platform is implemented to support program redefinition
with no risk to damaging the underlying code base. It should be accessible to
anyone with moderate scripting experience.

A major goal of the RAMP project is to prepackage these functionalities so
that they can be readily deployed as part of simulation system design. This goal
has been partially realized with respect to the RAM platform: annotations can
be added to the simulator's source code that direct the automatic generation of
Java code to integrate into the simulations' source and provide the functionality.
The following discussion assumes some familiarity with script or program
development.

⁴⁶⁷ B.2 Runtime alternative modules

Figure B.1 shows the RAM redefinition frame. The available RAMs appear as 468 radio buttons along the bottom of the frame. Each RAM is a set of options 469 for defining a relatively short Java method implementing some key aspect of 470 the simulation algorithm. For example, included in this simulation are the 471 implementation for cross immunity given in Eq. 1; the implementation for β 472 given in Eq. A.11; and the implementation for ϕ given in Eq. A.8; etc. Each 473 RAM initially contains only a single option, Option 0, the default, internally 474 defined implementation. Option 0 cannot be edited and appears for reference 475 purposes only. 476

Additional options may be added to each RAM containing code redefining the method. Two editor panes and one console pane are stacked in the frame and display the code and output of the RAM. These panes show the content associated with the currently selected RAM and option. The top editor pane contains the code for the method being redefined. The second editor pane contains definitions of any new help functions required by the definition in the top

Submitted on August 12, 2021




Figure B.1: RAM frame shows the implementation of a generic nearest-neighbor crossimmunity formulation C as the default. In the red-bordered insets are the cascading cross-immunity without (blue highlighted radio button 1) and with an idealized escape mutation (blue highlighted radio button 2), as formulated in Eqs. 1 and 2 respectively. Note the "+" button which allows for an unlimited number of alternatives to be set up using consecutive integer numbers for the new radio-buttons that appear and pertain to the selection of each alternative. Also, note the bottom list of functions that can be altered at runtime. The "load default" button on the upper left-hand side allows the user, when starting a new alternative, to insert the default code (which is immutable in radio-button 0) as a starting point. The frame also documents a list of terms in the upper panel that can be used to build any function.

⁴⁸³ pane. The console pane contains messages and output that are useful during the
⁴⁸⁴ development of the option. For convenience, a "Load Default" button initializes
⁴⁸⁵ the editor to an editable version of the Option 0 default to use as a starting
⁴⁸⁶ point.

Figure B.1 shows the Option 0 default definition for the cross immunity matrix function, as described by Eq. 1. Clicking the "+" button produced two new options, which appear in the insets. These option implement the alternative cascading cross immunity schemes presented in Eqs. 1 and 2. code appears below:

Submitted on August 12, 2021

⁴⁹⁷ Note that we have substituted the function pathSize for a hard-coded value ⁴⁹⁸ of 63. pathSize returns the number of pathogens, allowing us to use this ⁴⁹⁹ formulation for any choice of entropy. Documentation for pathSize is at the ⁵⁰⁰ top of the window in the list of available help functions and parameters. There ⁵⁰¹ is also more extensive documentation in a separate user guide (see Fig. B.2).

J-RAMP SEIVD IBM A-Mod Guide

rms wgetz

May 2021

 ω (Equation 9)

$$\omega_{ij}(t) = \begin{cases} 0 & \text{if } \mathbf{V}_j \text{ is null} \\ \frac{1}{1 + \left((t - \tau_{ij} - \sigma_{\mathbf{I}} - \sigma_{\mathbf{E}}) / t_j^{\text{half}} \right)^{\sigma}} & \text{if } t \ge \tau_{ij} + \sigma_{\mathbf{I}} + \sigma_{\mathbf{E}} \\ 1 & \text{if } t < \tau_{ii} + \sigma_{\mathbf{I}} + \sigma_{\mathbf{E}} \end{cases}$$

Code

```
double omega(int i, int j)
  if (i == 0) return 0.0;
                                    // Special case; A_0 never infected
  InfectedAgentState astate = getStateOf(i, j);
  if (astate == null || !(astate instanceof V)) return 0.0;
  double tau = tau(i,j);
  double sigI = sigmaI(j);
  double sigE = sigmaE(j);
  double timeSinceInfect = tau + sigI + sigE;
  if (time() <= timeSinceInfect) return 1.0;</pre>
  return 1/(1 + Math.pow((time() - timeSinceInfect)/tHalf(j), Params.sigma()));
3
Notes
 astate = getStateOf(i,j)
                                       astate is assigned to a Java InfectedAgentState
                                       object for agent i with respect to pathogen j.
                                      InfectedAgentState objects can either be state E, I, V
                                       or null (the latter for never-infected or dead agents.)
 astate == null || !(astate == V)
                                      astate is something other than state V
 tau(i,j)
                                       = \tau_{ij}
 sigmaI(j)
                                       = \sigma_I.
                                      =
= \sigma_{E.}
half
 sigmaE(j)
 tHalf(j)
                                       = \tau'_j
 time()
                                      = t.
 Params.sigma()
                                      = \sigma
```

Figure B.2: A description from our User Guide of the immunity waning function ω .

The platform duplicates a mini-development environment for building alternative definitions. Once code has been entered the "Compile" button checks the legality of the code and makes it available for use at runtime. Legally com-

Submitted on August 12, 2021

piled code will produce a "Compilation Successful" message. Errors will appear 505 with line numbers if they occur. Once the code is legal, the "Test" button can 506 be used with actual parameters entered into the small text fields to determine 507 correctness of the code. It is also possible to include print and println state-508 ments in the code during development to further check correctness. Output 509 from print statements will appear in the bottom console window. The entire 510 RAM set can be saved and will reappear during subsequent launches of the 511 simulator platform. 512

To use an alternate RAM definition at runtime simply select the dM-SEIRed option. (Selected options will be restored from a saved RAM set during subsequent launches.) The system will compile any uncompiled code the first time it is accessed. If an error occurs during a runtime compilation an alert will notify the user that the system is returning to the default definition of that RAM. At no time is the internal logic of the program overridden.

Finally, RAM option selection is part of the API described in the next section. This means that a script may run a simulation selecting different options at different points in time, using logic that considers the state of the model. For example, such an adaptive protocol might be appropriate for determining the contact rate κ .

⁵²⁴ B.3 Application programming interface

The API is a simple bytecode¹ called BPL (Blackbox Programming Language) 525 that addresses all available user interactions with the simulator. Instructions 526 fall into three categories: parameter assignment and retrieval; simulator oper-527 ation; and data retrieval. A complete list of instructions is shown in Fig. B.3. 528 Instructions are comprised of opcodes (e.g., reset, step, get) followed by 0 529 or more arguments. Every BPL operation returns a result, even if empty, for 530 synchronization purposes. A string consisting of a sequence of opcodes and 531 arguments may be submitted to the BPL interpreter, an example of which is 532 shown in the notes in Fig. B.3. 533

534

Parameter assignment and retrieval. Every user-configurable element (in-535 cluding random number generator seeds) is addressed from BPL using a unique 536 three-letter "airport code" (see Table. B.31). Additionally, pathogens are ad-537 dressed by their id number (0 to $2^J - 1$) and agent states using identifiers S, E, 538 I, V, DI+ and DD (the latter two represent ΔI and ΔD , respectively). RAM 539 options are addressed in setOption and getOption using the name of the RAM 540 (e.g., "crossImmune"). Get and set operations can be used on each of these with 541 the exception of ENT (variant entropy), which is read-only. 542

543

Simulator operation. Simulation runs begin by executing the BPL reset
instruction, followed by step, run_for or run. The BPL interpreter operates
synchronously with the simulator by waiting to process subsequent commands
during a simulation run. Operational instructions can be interspersed with parameter set/get or data retrieval to use in runtime decision-making. Note that

¹a *bytecode* is computer source code that is processed immediately by a program, usually referred to as an interpreter or virtual machine.

Submitted on August 12, 2021

the **reset** operation restores the simulator to its state at the time of the last **reset**, so that no parameter changes made during a run are persistent.

551

⁵⁵² Data retrieval Operations to obtain the current population in each state, and ⁵⁵³ to retrieve the runtime population history of each state and pathogen are also ⁵⁵⁴ included. These can be easily transformed into R data frames, for example, for ⁵⁵⁵ further analysis.

556

Scripting can be deployed using either one of the two on-board script interpreter interfaces, or remotely from another platform using drivers provided with the simulator. The remote drivers use TCP/IP *sockets*. Sockets are integral to Internet communication, and so are found on any system supporting the Internet. In this case the simulator acts as a server fielding API requests from the remote drivers.

On our main dashboard, we provide two scripting windows that are opened 563 using the "S On" and "JS On" buttons (see button second and third from left at 564 bottom of Fig. 2A). The former allows the user to write simulation driver scripts 565 directly as command strings. (The commands listed in Fig. B.3 are accessed 566 by pressing the "Command Reference" button in the "S On" window.) This 567 window is used primarily to test and monitor scripts intended to be deployed on 568 a remote platform. The JS window contains a Nashorn Javascript interpreter 569 enhanced to accept and execute BPL operations. Scripts can developed, saved, 570 and used to drive the simulator from this interpreter. For example, Fig. B.4, lists 571 the code used to implement the adaptive vaccination programs. The SEIV object 572 referenced in this code contains methods corresponding to the BPL operations 573 detailed in Fig. B.3. 574

Name	Math	Code	Name	Math	Code		
Epidemic codes							
% mortality	p_{lpha}	MOR	transmission	β	XMT		
env. persist.	η	PST	within-host replication	λ	INV		
median latent period	$\sigma_{ m E}$	MLP	median infectious period	$\sigma_{ m I}$	MIP		
population size	N_0	POP	contact rate	$\bar{\kappa}$	CPT		
mutation rate	μ	MUR	abruptness of waning	σ_{1}	AOW		
cross immunity	c	CIM	waning half-life	t^{half}	WHA		
seas. trans. peturb	$\delta_{ m season}$	STP	seas. trans. shift	θ	STS		
seas. trans. period	k	PER	adap. contact param.	$p_{\mathrm{I}_{-}}^{\mathrm{half}}$	IPC		
variant entropy	J	ENT	shedding rate	ζ	SHD		
-[2pt] mortality peturb	δ_{lpha}	MOP	transmission perturb	δ_{eta}	TRP		
Vaccination codes							
enable vaccination		VEN	vaccine on/off	$t_v^{\mathrm{on}}/t_v^{\mathrm{off}}$	VOO		
variant valency type	VA#, #	=1,,4	selection composition	5,0	VCP		
vaccinate susc. only		VSU	vaccinate non-infectious		NVI		
vaccinate non-vacc.		VNV					

Table B1: Airport codes for	, 1	• 1 1 1 •	1 1 1 1 1 1
Table RI. Airport codes for	noromotor ond	variables lised i	n the model alcorithm
	parameter and	\cdot variables used i	

Getz et al.

BPL Reference

Commands

reset	Resets simulation with initial slider/switch values.
restart	Resets simulation with current slider/switch values.
run_for T	Run the simulation from the current time for $\boldsymbol{\tau}$ steps.
run	Run the simulation for the number of steps set by the last run_for command.
step	Single-step the simulation one time unit.
get time	Returns current simulation time.
getLimit XXX	Returns lower and upper values of limit control labeled xxx on separate lines.
getPath XXX id	Returns value of parameter xxx in pathogen id.
getOption op	Returns the option number for operator op in the operator overrides.
get XXX	Returns value of non-limit control labeled xxx.
setLimit XXX lo hi	Sets the limit control XXX to limits 10 hi.
setPath XXX id Y	Sets value of parameter XXX in pathogen id to Y.
setOption op Y	Sets option for operator op in the operator overrides to option number Y.
set XXX Y	Sets value of non-limit control xxx to x.
pathPop id Z	id is a pathogen id and z must be one of the agent state identifiers (S, E, I, V, DI+, DD). Returns the current population in state z with respect to pathogen id.
totPop Z	z must be one of the agent state identifiers (S, E, I, V, DI+, DD). Returns the total population in state z.
timeTrail	Returns the array of timesteps for use in a table with other trail data.
pathTrail idZ	id is a pathogen id and z must be one of the agent state identifiers (S, E, I, V, DI+, DD). The population array for that pathogen and for that state over time is returned.
popTrail Z	z must be one of the agent state identifiers (S, E, I, V, DI+, DD). The array of the entire population over time for that state is returned.
sleep T	NMBPL processor sleeps for τ milliseconds.
	(May be used for synchronization during longer simulations.)

Notes

- · Commands without explicit return do not return a value
- get and set use the 3-letter "airport codes" associated with each control
- · Commands may be sequenced; e.g.

run_for 50 set XMT 1.5 run popTrail I

will run for 50 timesteps, set the transmission paramter to 1.5, run for another 50, and return the 100 population values of I.

- · Returned values are separated by newlines. When command sequences are sent remotely, left and right brackets (i.e. \[\ and \]\) followed by newlines enclose the sequence of returned values, even if the sequence is empty; e.g., [\n50\n100\n1000\n]
- When using trail: if embedded in a command sequence, this must be the only command that returns a value (since the array returned by each of them will be embedded in the set of answers returned by the command sequence.)
- Use the console to test command sequences before using them remotely.
 BPL uses TCP/IP sockets to implement a client-server protocol on the local host. Clients initiate a connection on a specified port (default is 8080) and transmit a command sequence; the SEIVAgent server replies with the result and closes the connection.
- · Changes to the port number, if saved to Preferences, will reappear in subsequent uses. Multiple instances of Numerus can run concurrently using different ports. Changes will automatically restart the server.
- Restart button restarts the server.

Figure B.3: The list of Blackbox Programming Language (BPL) commands that can be used to write a simulation driver script, using the three-letter "airport codes" listed in Table A1 to access the parameters and variables in our coded algorithm. This list of commands can be accessed using the "Command Reference" button at the bottom of the Scripting Window.

Submitted on August 12, 2021

Getz et al.

	Reference New Script Open Script Save 1 Nashorn 1.8.0 (es6) 2 3/35 Start: running for 365 days w/o vaccinations 3 time 365 VAucinations start 4 time 365 VAucinations start 4	Scipt Save As 1 var script = function() { 2 var obj = new Object(); 3 obj.getPop = function() { 4 var ans = new Array(); 5 obj.getPop = function() { 5 o
1234567890123456789012234567890122345567890122345678	<pre>ar script = function() { vir obj = new Object(); vor obj = new Object(); var ant = new Aray(); var pathölse = Math.pow(2, antropy); for (var j = 0; j < pathölse; j++) { ans(j = 4EEU, pathölse; j++) { ans(j = 4EEU, pathölse; j++) { ans(j = 4EEU, pathölse; j++) { if (all > best(); best() = [-1, 0]; var best() = [-1, 0]; var best() = [-1, 0]; var loog = function() { var loog = obj.getTwoBest(lPop); var twoBest = twoBest[]; if (oost() = [-1, 0]; val estest = twoBest[]; val estest = twoBest[]; val estest = twoBest[]; val = "sEUV.get(VAl), "VA2="sEUV.get(VA2);; return; "VA1="sEUV.get(VA1], "VA2="sEUV.get(VA2);; return; best() best() best(); best(); best(); best(); best(); val estest = twoBest[]; val estert = twoBest[]; val estest = twoBest[]; val estest = twoBest[]; val estest = twoBest[]; val estest = twoBest[];</pre>	<pre>for (var j = 1; j <= 4; j++) { SETV.set("VX+j, "off"); } SETV.set(VX), best[0]); if (nextBest[1] > 10) SETV.set(VX2, nextBest[0]); if (nextBest[1] > 10) SETV.set(VX2, nextBest[0]); console.log("time", SETV.get("time"), "VX1="SETV.get(VX1), "VX2="SETV.get(VX2)); } b), init = function(vaccOn) { SETV.set("VX+j, "off"); for (var j = 1; j <= 4; j++) { SETV.set("VX+j, "off"); } SETV.set(VX1, 0); } // n = total days, n = vacc period dbj.rum for("day); console.log("Start: running for", delay, "days w/o vaccinations" SETV.set(Init(VOO, vaccOn, 2000); SETV.set(Init("no", SETV.get("time"), "Vaccinations start"); dbj.int(n = (notion(n, n, delay) { console.log("time", SETV.get("time"), "Vaccinations start"); dbj.int(n = (notion(n), n, delay) { console.log("time", SETV.get("time"), "Vaccinations start"); dbj.int(n = (notion(n), n, delay) { console.log("time", SETV.get("time"), "Vaccinations start"); dbj.int(n = (notion(n), n, delay) { console.log("time", SETV.get("time"), "Vaccinations start"); dbj.loop(n); for (var i = 0; i < p: i++) { stj.loop(n); j; return obj; j) // 155 = total days, 40 = vacc period, 30 = delay var go = function() { scipt.run(100, 15, 365); } </pre>
	Clear Console Reset Console Go	71 // 150 = total days, 40 = vacc period, 30 = delay 72 var qo = function() { 73 script.run(1100, 15, 365); 74) Stop ClearScript

Figure B.4: The JS scripting window accessed by selecting the "JS On" button in the main dashboard (see button second from left at bottom of Fig. 2A). The script shown here (broken into two columns 1-74 and overlaid over JS window) was used to execute the adaptive vaccination strategy discussed in the main text.

575 B.4 R Integration

As previously mentioned, the API supports remote control of the simulator from
independent platforms using the operating system's socket interface². Of particular interest is integration with the R statistical programming environment. An
R-package called "seiv" acts as a driver by synchronously issuing BPL command
strings and waiting for results. Consequently, a simulation can be driven entirely
from within the R platform, treating the simulator as a "virtual package".

Fig. B.5 shows the code used to run the simulator multiple times with different random number generator seeds. Following each run, the time history of the population in the I, DI+ and DD states is extracted directly to an R data frame (without the need to save, for example, in a comma-separated list). At the end of the run sequence the data frame is used to build the plots shown in Fig. 3D & E.

R could be used in a more direct way by analyzing data at various points throughout a single run and adjusting parameters programmatically, similar to the adaptive vaccination strategy carried out in Javascript, only taking advantage of the R environment's powerful toolkit.

 $^{^2\}mathrm{By}$ using internet sockets, the simulator and R platform could conceivably run on different systems.

Submitted on August 12, 2021

Getz et al.




Figure B.5: Our M-SEIR can be treated as an R-package called "seiv" and run as such in conjunction with other packages, such as ggplot2 and reshape to conduct multiple simulations and then carry out data and statistical analyses of the simulation results. The code shown here was used to produce the plots illustrated in Fig. 3D & E.